## A. ORIGIN OF THE REPORT

A1		Name of contracting Party:
		Republic of Moldova
A3k		Web page
		www.ms.gov.md
1		Period of reporting:
	1	Start date
		January 2021
	1	End date
		January 2023

## **B1. TOBACCO CONSUMPTION**

B1		Prevalence of tobacco use
B11		Smoking prevalence in the adult population (all) (Please provide prevalence data for total adult population, and identify the age considered, e.g. 15 years old and over, 18-64 years; see B112)
1_SQ001		Current smokers
	1_SQ001	MALE [Prevalence (%) (please include all smoking tobacco products in prevalence data)]  52
	1_SQ002	MALE [Average number of the most-consumed smoking tobacco product used per day]  16,2
	2_SQ001	FEMALE [Prevalence (%) (please include all smoking tobacco products in prevalence data)]  7,7
	2_SQ002	FEMALE [Average number of the most-consumed smoking tobacco product used per day]  11,8
	3_SQ001	TOTAL (males and females) [Prevalence (%) (please include all smoking tobacco products in prevalence data)]  29,9
	3_SQ002	TOTAL (males and females) [Average number of the most-consumed smoking tobacco product used per day]  15.8
1_SQ001		Daily smokers
	1_SQ001	MALE [Prevalence (%) (please include all smoking tobacco products in prevalence data)]  46
	1_SQ002	MALE [Average number of the most-consumed smoking tobacco product used per day]  16
	2_SQ001	FEMALE [Prevalence (%) (please include all smoking tobacco products in prevalence data)]
	2_SQ002	FEMALE [Average number of the most-consumed smoking tobacco product used per day]
	3_SQ001	TOTAL (males and females) [Prevalence (%) (please include all smoking tobacco products in prevalence data)]
	3_SQ002	24,4  TOTAL (males and females) [Average number of the most-consumed smoking tobacco product used per day]
1_SQ001		16 Occasional smokers

	1_SQ001	MALE [Prevalence (%) (please include all smoking tobacco products in prevalence data)]
		4,6
	2_SQ001	FEMALE [Prevalence (%) (please include all smoking tobacco products in prevalence data)]
		1,5
	3_SQ001	TOTAL (males and females) [Prevalence (%) (please include all smoking tobacco products in prevalence data)]
		2.6
1_SQ001		Former smokers
	1_SQ001	MALE [Prevalence (%) (please include all smoking tobacco products in prevalence data)]
		24
	2_SQ001	FEMALE [Prevalence (%) (please include all smoking tobacco products in prevalence data)]
		5
	3_SQ001	TOTAL (males and females) [Prevalence (%) (please include all smoking tobacco products in prevalence data)]
		14,4
1_SQ001		Never smokers
	1_SQ001	MALE [Prevalence (%) (please include all smoking tobacco products in prevalence data)]
		40
	2_SQ001	FEMALE [Prevalence (%) (please include all smoking tobacco products in prevalence data)]
		82
	3_SQ001	TOTAL (males and females) [Prevalence (%) (please include all smoking tobacco products in prevalence data)]
		58
B111		Please indicate the smoking tobacco products included in calculating prevalence for question B11:
		Include all smoking tobacco products: Cigarettes, cigarillos, cigars, heated tobacco products, e-cigarettes
1_SQ001		Please indicate the age range to which the data used to answer question B11 refer:
	1_SQ001	Age range [From]
		18
	1_SQ002	Age range [To]
		69
B113A		Please indicate the year of the data used to answer question B11:
		2021
B113B		Please indicate the source of the data used to answer question B11:
		STEPS Report on risk factors for non-communicable diseases, Republic of Moldova, 2022
SQ001		Please provide the definitions of "current smoker", "daily smoker", "occasional smoker", "former smoker" and "never smoker" used in this report.

	00004	Current employ
	SQ001	Current smoker
	SQ002	a person who used a tobacco product in the last month  Daily smoker
	3002	a person who smoke at least once a day, every day
	SQ003	Occasional smoker
	00000	a person who smokes only in some days, not every day
	SQ004	Former smoker
	00004	
	SQ005	a person who does not smoke for at least 6 months  Never smoker
	0000	
B115		a person who has smoked more than 100 cigarettes in their lifetime  Please provide a brief explanation of the trend in smoking prevalence in the adult
Billo		population in the past two years or since submission of your last report.
		the smoking prevalence in the adult population in the last two years is increasing mainly due to increased consumption of heated tobacco products and e-cigarettes
B12a_B12x1		Smoking prevalence in the adult population (by age groups)(If data are available, please provide prevalence data by age group, and identify the age group considered, preferably by 10-year categories, e.g. 25-34, 35-44 years)
	B12a_B12x1	MALES - current smokers1 [Range - start age]
		18
	B12a_B12x3	MALES - current smokers1 [Range - end age]
	_	29
	B12a_B12x2	MALES - current smokers1 [Prevalence (%) (please include all smoking tobacco products in prevalence data)]
		51,4
	B12b_B12x1	MALES - current smokers1 [Range - start age]
		30
	B12b_B12x3	MALES - current smokers1 [Range - end age]
		44
	B12b_B12x2	MALES - current smokers1 [Prevalence (%) (please include all smoking tobacco products in prevalence data)]
		56,1
	B12c_B12x1	MALES - current smokers1 [Range - start age]
		45
	B12c_B12x3	MALES - current smokers1 [Range - end age]
		59
	B12c_B12x2	MALES - current smokers1 [Prevalence (%) (please include all smoking tobacco products in prevalence data)]
		46,3
	B12d_B12x1	MALES - current smokers1 [Range - start age]
		60

	B12d_B12x3	MALES - current smokers1 [Range - end age]
		69
	B12d_B12x2	MALES - current smokers1 [Prevalence (%) (please include all smoking tobacco products in prevalence data)]
		33,3
	B12e_B12x1	MALES - current smokers1 [Range - start age]
	B12e_B12x3	MALES - current smokers1 [Range - end age]
	B12e_B12x2	MALES - current smokers1 [Prevalence (%) (please include all smoking tobacco products in prevalence data)]
	B12ee_B12x1	MALES - current smokers1 [Range - start age]
	B12ee_B12x3	MALES - current smokers1 [Range - end age]
	B12ee_B12x2	MALES - current smokers1 [Prevalence (%) (please include all smoking tobacco products in prevalence data)]
	B12eee_B12x1	MALES - current smokers1 [Range - start age]
	B12eee_B12x3	MALES - current smokers1 [Range - end age]
	B12eee_B12x2	MALES - current smokers1 [Prevalence (%) (please include all smoking tobacco products in prevalence data)]
	B12eeee_B12x	MALES - current smokers1 [Range - start age]
	B12eeee_B12x	MALES - current smokers1 [Range - end age]
	B12eeee_B12x	MALES - current smokers1 [Prevalence (%) (please include all smoking tobacco products in prevalence data)]
	B12f_B12x1	FEMALES - current smokers1 [Range - start age]
		18
	B12f_B12x3	FEMALES - current smokers1 [Range - end age]
	B12f_B12x2	FEMALES - current smokers1 [Prevalence (%) (please include all smoking tobacco products in prevalence data)]
		6,6
	B12g_B12x1	FEMALES - current smokers1 [Range - start age]
I	I	I

	30
B12g_B12x3	FEMALES - current smokers1 [Range - end age]
	44
B12g_B12x2	FEMALES - current smokers1 [Prevalence (%) (please include all smoking tobacco products in prevalence data)]
	9.8
B12h_B12x1	FEMALES - current smokers1 [Range - start age]
	45
B12h_B12x3	FEMALES - current smokers1 [Range - end age]
	59
B12h_B12x2	FEMALES - current smokers1 [Prevalence (%) (please include all smoking tobacco products in prevalence data)]
	4,8
B12i_B12x1	FEMALES - current smokers1 [Range - start age]
	60
B12i_B12x3	FEMALES - current smokers1 [Range - end age]
	69
B12i_B12x2	FEMALES - current smokers1 [Prevalence (%) (please include all smoking tobacco products in prevalence data)]
	1,9
B12j_B12x1	FEMALES - current smokers1 [Range - start age]
B12j_B12x3	FEMALES - current smokers1 [Range - end age]
B12j_B12x2	FEMALES - current smokers1 [Prevalence (%) (please include all smoking tobacco products in prevalence data)]
B12jj_B12x1	FEMALES - current smokers1 [Range - start age]
B12jj_B12x3	FEMALES - current smokers1 [Range - end age]
B12jj_B12x2	FEMALES - current smokers1 [Prevalence (%) (please include all smoking tobacco products in prevalence data)]
B12jjj_B12x1	FEMALES - current smokers1 [Range - start age]
B12jjj_B12x3	FEMALES - current smokers1 [Range - end age]
B12jjj_B12x2	FEMALES - current smokers1 [Prevalence (%) (please include all smoking tobacco products in prevalence data)]

FEMALES - current smokers1 [Range - start age]
FEMALES - current smokers1 [Range - end age]
FEMALES - current smokers1 [Prevalence (%) (please include all smoking tobacco products in prevalence data)]
TOTAL (males and females) - current smokers1 [Range - start age]  18
TOTAL (males and females) - current smokers1 [Range - end age]
TOTAL (males and females) - current smokers1 [Prevalence (%) (please include all smoking tobacco products in prevalence data)]
29,4
TOTAL (males and females) - current smokers1 [Range - start age] 30
TOTAL (males and females) - current smokers1 [Range - end age]
TOTAL (males and females) - current smokers1 [Prevalence (%) (please include all smoking tobacco products in prevalence data)]
33,9
TOTAL (males and females) - current smokers1 [Range - start age]
TOTAL (males and females) - current smokers1 [Range - end age]  59
TOTAL (males and females) - current smokers1 [Prevalence (%) (please include all smoking tobacco products in prevalence data)]
25,1
TOTAL (males and females) - current smokers1 [Range - start age]  60
TOTAL (males and females) - current smokers1 [Range - end age]
TOTAL (males and females) - current smokers1 [Prevalence (%) (please include all smoking tobacco products in prevalence data)]
16,5
TOTAL (males and females) - current smokers1 [Range - start age]
TOTAL (males and females) - current smokers1 [Range - end age]
TOTAL (males and females) - current smokers1 [Prevalence (%) (please include all smoking tobacco products in prevalence data)]

	B1200_B12x1	TOTAL (males and females) - current smokers1 [Range - start age]
	B1200_B12x3	TOTAL (males and females) - current smokers1 [Range - end age]
	B1200_B12x2	TOTAL (males and females) - current smokers1 [Prevalence (%) (please include all smoking tobacco products in prevalence data)]
	B12000_B12x1	TOTAL (males and females) - current smokers1 [Range - start age]
	B12000_B12x3	TOTAL (males and females) - current smokers1 [Range - end age]
	B12000_B12x2	TOTAL (males and females) - current smokers1 [Prevalence (%) (please include all smoking tobacco products in prevalence data)]
	B120000_B12x	TOTAL (males and females) - current smokers1 [Range - start age]
	B120000_B12x	TOTAL (males and females) - current smokers1 [Range - end age]
	B120000_B12x	TOTAL (males and females) - current smokers1 [Prevalence (%) (please include all smoking tobacco products in prevalence data)]
B121		Please indicate the smoking tobacco products included in calculating prevalence for question B12:
		Include all smoking tobacco products: Cigarettes, cigarillos, cigars, heated tobacco products, e-cigarettes
B122A		Please indicate the year of the data used to answer question B12:
B122B		Please indicate the source of the data used to answer question B12:
		STEPS Report on risk factors for non-communicable diseases, Republic of Moldova, 2022
B123		Please provide a brief explanation of the trend in current smoking prevalence by age group in the past two years or since submission of your last report, if data are available.
		the smoking prevalence in the last two years is increasing mainly in age group 18-29 years due to increased consumption of heated tobacco products and e-cigarettes
B13		Prevalence of smokeless tobacco use in the adult population (all) (Please provide prevalence data for total adult population, and identify the age considered in B132, e.g. 15 years old and over, 18–64 years; see B132)
1_B13x1		Males
	1_B13x1	Current users [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]
		0
	2_B13x1	Daily users [Prevalence (%) (please include all smokeless tobacco products in prevalence

		data)]
		О
	3_B13x1	Occasional users [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]
		0,2
	4_B13x1	Former users [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]
		0,5
	5_B13x1	Never users [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]
		99
1_B13x1		Females
	1_B13x1	Current users [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]
		0
	2_B13x1	Daily users [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]
		0
	3_B13x1	Occasional users [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]
		0
	4_B13x1	Former users [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]
		0
	5_B13x1	Never users [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]
		0
1_B13x1		TOTAL (males and females)
	1_B13x1	Current users [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]
		0
	2_B13x1	Daily users [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]
		0
	3_B13x1	Occasional users [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]
		0,2
	4_B13x1	Former users [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]
		0,5
	5_B13x1	Never users [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]

		99
B131		Please indicate the smokeless tobacco products included in calculating prevalence for question B13:
		chewing tobacco, snus
1_SQ001		Please indicate the age range to which the data used to answer question B13 refer:
	1_SQ001	Age range [From]
		18
	1_SQ002	Age range [To]
		69
B133A		Please indicate the year of the data used to answer question B13:
		2021
B133B		Please indicate the source of the data used to answer question B13:
		STEPS Report on risk factors for non-communicable diseases, Republic of Moldova, 2022
SQ001		Please provide the definitions of "current user", "daily user", "occasional user", "former user" and "never user" (of smokeless tobacco products) used in this report in the space below.
	SQ001	Current user
		a person who used a smokeless tobacco product in the last month
	SQ002	Daily user
		a person who used a smokeless tobacco product at least once a day, every day
	SQ003	Occasional user
		a person who used a smokeless tobacco product only in some days, not every day
	SQ004	Former user
		a person who does not used a smokeless tobacco product for at least 6 months
	SQ005	Never user
		a person who never used a smokeless tobacco product in their lifetime
B135		Please provide a brief explanation of the trend in smokeless tobacco use in the adult population in the past two years or since submission of your last report.
		smokeless tobacco use isn't popular, less than 1%
B12a_B12x1		Prevalence of smokeless tobacco use in the adult population (current users) by age group (by age groups)(If data are available, please provide prevalence data by age group, and identify the age group considered, preferably by 10-year categories, e.g. 25-34, 35-44 years)
	B12a_B12x1	MALES - current users2 [Age group (adults)]
		18-29
	B12a_B12x2	MALES - current users2 [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]
		0
	B12b_B12x1	MALES - current users2 [Age group (adults)]
		30-44

B12b_B12x2	MALES - current users2 [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]
	0
B12c_B12x1	MALES - current users2 [Age group (adults)]
	45-59
B12c_B12x2	MALES - current users2 [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]
	0
B12d_B12x1	MALES - current users2 [Age group (adults)]
	60-69
B12d_B12x2	MALES - current users2 [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]
	0
B12e_B12x1	MALES - current users2 [Age group (adults)]
B12e_B12x2	MALES - current users2 [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]
B12ee_B12x1	MALES - current users2 [Age group (adults)]
B12ee_B12x2	MALES - current users2 [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]
B12eee_B12x1	MALES - current users2 [Age group (adults)]
B12eee_B12x2	MALES - current users2 [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]
B12eeee_B12x	MALES - current users2 [Age group (adults)]
B12eeee_B12x 2	MALES - current users2 [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]
B12f_B12x1	FEMALES - current users2 [Age group (adults)]
	18-29
B12f_B12x2	FEMALES - current users2 [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]
	0
B12g_B12x1	FEMALES - current users2 [Age group (adults)]
	30-44
_	<del>i</del>

		0
	B12h_B12x1	FEMALES - current users2 [Age group (adults)]
		45-59
	B12h_B12x2	FEMALES - current users2 [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]
		0
	B12i_B12x1	FEMALES - current users2 [Age group (adults)]
		60-69
	B12i_B12x2	FEMALES - current users2 [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]
		0
	B12j_B12x1	FEMALES - current users2 [Age group (adults)]
	B12j_B12x2	FEMALES - current users2 [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]
	B12jj_B12x1	FEMALES - current users2 [Age group (adults)]
	B12jj_B12x2	FEMALES - current users2 [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]
	B12jjj_B12x1	FEMALES - current users2 [Age group (adults)]
	B12jjj_B12x2	FEMALES - current users2 [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]
	B12jjjj_B12x1	FEMALES - current users2 [Age group (adults)]
	B12jjjj_B12x2	FEMALES - current users2 [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]
	B12k_B12x1	TOTAL (males and females) - current users2 [Age group (adults)]
		18-29
	B12k_B12x2	TOTAL (males and females) - current users2 [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]
		0
	B12l_B12x1	TOTAL (males and females) - current users2 [Age group (adults)]
		30-44
	B12I_B12x2	TOTAL (males and females) - current users2 [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]
		0
	B12m_B12x1	TOTAL (males and females) - current users2 [Age group (adults)]
I	I	I

		45-59
	B12m_B12x2	TOTAL (males and females) - current users2 [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]
		0
	B12n_B12x1	TOTAL (males and females) - current users2 [Age group (adults)]
		60-69
	B12n_B12x2	TOTAL (males and females) - current users2 [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]
		0
	B120_B12x1	TOTAL (males and females) - current users2 [Age group (adults)]
	B12o_B12x2	TOTAL (males and females) - current users2 [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]
	B1200_B12x1	TOTAL (males and females) - current users2 [Age group (adults)]
	B1200_B12x2	TOTAL (males and females) - current users2 [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]
	B12000_B12x1	TOTAL (males and females) - current users2 [Age group (adults)]
	B12000_B12x2	TOTAL (males and females) - current users2 [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]
	B120000_B12x	TOTAL (males and females) - current users2 [Age group (adults)]
	B120000_B12x 2	TOTAL (males and females) - current users2 [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]
B141		Please indicate the smokeless tobacco products included in the answer to question B14:
DITI		chewing tobacco, snus
B142A		Please indicate the year of the data used to answer question B14:
BIAZI		2021
B142B		Please indicate the source of the data used to answer question B14:
2.120		·
B143		STEPS Report on risk factors for non-communicable diseases, Republic of Moldova, 2022  Please provide a brief explanation of the trend in current use of smokeless tobacco by adult
טדוע		age groups in the past two years or since submission of your last report.
		smokeless tobacco use isn't popular, less than 1%, mainly former users
B15a_B15x1		Tobacco use by ethnic group(s) (please include all smoking or smokeless tobacco products in prevalence data)
	B15a_B15x1	Current users 3 [Ethnic group(s)]

B15a_B15x2	Current users 3 [MALES - Prevalence (%)]
B15a_B15x3	Current users 3 [FEMALES - Prevalence (%)]
B15a_B15x4	Current users 3 [TOTAL (males and females) - Prevalence (%)]
B15b_B15x1	Current users 3 [Ethnic group(s)]
B15b_B15x2	Current users 3 [MALES - Prevalence (%)]
B15b_B15x3	Current users 3 [FEMALES - Prevalence (%)]
B15b_B15x4	Current users 3 [TOTAL (males and females) - Prevalence (%)]
B15c_B15x1	Current users 3 [Ethnic group(s)]
B15c_B15x2	Current users 3 [MALES - Prevalence (%)]
B15c_B15x3	Current users 3 [FEMALES - Prevalence (%)]
B15c_B15x4	Current users 3 [TOTAL (males and females) - Prevalence (%)]
B15d_B15x1	Current users 3 [Ethnic group(s)]
B15d_B15x2	Current users 3 [MALES - Prevalence (%)]
B15d_B15x3	Current users 3 [FEMALES - Prevalence (%)]
B15d_B15x4	Current users 3 [TOTAL (males and females) - Prevalence (%)]
B15e_B15x1	Current users 3 [Ethnic group(s)]
B15e_B15x2	Current users 3 [MALES - Prevalence (%)]
B15e_B15x3	Current users 3 [FEMALES - Prevalence (%)]
B15e_B15x4	Current users 3 [TOTAL (males and females) - Prevalence (%)]
<del> </del>	<del> </del>

B151		Please indicate the tobacco products included in the answer to question B15:
		no data on tobacco use by ethnic groups
1_SQ001		Please indicate the age range to which the data used to answer question B15 refer:
	1_SQ001	Age range [From]
	1_SQ002	Age range [To]
B153A		Please indicate the year of the data used to answer question B15:
B153B		Please indicate the source of the data used to answer question B15:
		no data on tobacco use by ethnic groups
B16a_B16x1		Tobacco use by young persons (please include all smoking or smokeless tobacco products in prevalence data)
	B16a_B16x1	BOYS - Current users 4 [Age range]
	D40 D40 0	13-15 years
	B16a_B16x2	BOYS - Current users 4 [SMOKING TOBACCO - Prevalence (%)]
		17,5
	B16a_B16x3	BOYS - Current users 4 [SMOKELESS TOBACCO - Prevalence (%) ]
		2,1
	B16a_B16x4	BOYS - Current users 4 [WATER PIPE - Prevalence (%) ]
	B16b_B16x1	BOYS - Current users 4 [Age range]
	B16b_B16x2	BOYS - Current users 4 [SMOKING TOBACCO - Prevalence (%)]
	B16b_B16x3	BOYS - Current users 4 [SMOKELESS TOBACCO - Prevalence (%) ]
	B16b_B16x4	BOYS - Current users 4 [WATER PIPE - Prevalence (%) ]
	B16c_B16x1	BOYS - Current users 4 [Age range]
	B16c_B16x2	BOYS - Current users 4 [SMOKING TOBACCO - Prevalence (%)]
	B16c_B16x3	BOYS - Current users 4 [SMOKELESS TOBACCO - Prevalence (%) ]
	B16c_B16x4	BOYS - Current users 4 [WATER PIPE - Prevalence (%) ]

B16d_B16x1	BOYS - Current users 4 [Age range]
B16d_B16x2	BOYS - Current users 4 [SMOKING TOBACCO - Prevalence (%)]
B16d_B16x3	BOYS - Current users 4 [SMOKELESS TOBACCO - Prevalence (%) ]
B16d_B16x4	BOYS - Current users 4 [WATER PIPE - Prevalence (%) ]
B16e_B16x1	BOYS - Current users 4 [Age range]
B16e_B16x2	BOYS - Current users 4 [SMOKING TOBACCO - Prevalence (%)]
B16e_B16x3	BOYS - Current users 4 [SMOKELESS TOBACCO - Prevalence (%) ]
B16e_B16x4	BOYS - Current users 4 [WATER PIPE - Prevalence (%) ]
B16ee_B16x1	BOYS - Current users 4 [Age range]
B16ee_B16x2	BOYS - Current users 4 [SMOKING TOBACCO - Prevalence (%)]
B16ee_B16x3	BOYS - Current users 4 [SMOKELESS TOBACCO - Prevalence (%) ]
B16ee_B16x4	BOYS - Current users 4 [WATER PIPE - Prevalence (%) ]
B16eee_B16x1	BOYS - Current users 4 [Age range]
B16eee_B16x2	BOYS - Current users 4 [SMOKING TOBACCO - Prevalence (%)]
B16eee_B16x3	BOYS - Current users 4 [SMOKELESS TOBACCO - Prevalence (%) ]
B16eee_B16x4	BOYS - Current users 4 [WATER PIPE - Prevalence (%) ]
B16eeee_B16x	BOYS - Current users 4 [Age range]
B16eeee_B16x	BOYS - Current users 4 [SMOKING TOBACCO - Prevalence (%)]
B16eeee_B16x	BOYS - Current users 4 [SMOKELESS TOBACCO - Prevalence (%)]
†	<del> </del>

B16eeee_B16x 4	BOYS - Current users 4 [WATER PIPE - Prevalence (%) ]
B16f_B16x1	GIRLS - Current users 4 [Age range]
	13-15 years
B16f_B16x2	GIRLS - Current users 4 [SMOKING TOBACCO - Prevalence (%)]
	9.5
B16f_B16x3	GIRLS - Current users 4 [SMOKELESS TOBACCO - Prevalence (%) ]
	1.4
B16f_B16x4	GIRLS - Current users 4 [WATER PIPE - Prevalence (%) ]
B16g_B16x1	GIRLS - Current users 4 [Age range]
B16g_B16x2	GIRLS - Current users 4 [SMOKING TOBACCO - Prevalence (%)]
B16g_B16x3	GIRLS - Current users 4 [SMOKELESS TOBACCO - Prevalence (%) ]
B16g_B16x4	GIRLS - Current users 4 [WATER PIPE - Prevalence (%) ]
B16h_B16x1	GIRLS - Current users 4 [Age range]
B16h_B16x2	GIRLS - Current users 4 [SMOKING TOBACCO - Prevalence (%)]
B16h_B16x3	GIRLS - Current users 4 [SMOKELESS TOBACCO - Prevalence (%) ]
B16h_B16x4	GIRLS - Current users 4 [WATER PIPE - Prevalence (%) ]
B16i_B16x1	GIRLS - Current users 4 [Age range]
B16i_B16x2	GIRLS - Current users 4 [SMOKING TOBACCO - Prevalence (%)]
B16i_B16x3	GIRLS - Current users 4 [SMOKELESS TOBACCO - Prevalence (%) ]
B16i_B16x4	GIRLS - Current users 4 [WATER PIPE - Prevalence (%) ]
B16j_B16x1	GIRLS - Current users 4 [Age range]
B16j_B16x2	GIRLS - Current users 4 [SMOKING TOBACCO - Prevalence (%)]

B16j_B16x3	GIRLS - Current users 4 [SMOKELESS TOBACCO - Prevalence (%) ]
B16j_B16x4	GIRLS - Current users 4 [WATER PIPE - Prevalence (%) ]
B16jj_B16x1	GIRLS - Current users 4 [Age range]
B16jj_B16x2	GIRLS - Current users 4 [SMOKING TOBACCO - Prevalence (%)]
B16jj_B16x3	GIRLS - Current users 4 [SMOKELESS TOBACCO - Prevalence (%) ]
B16jj_B16x4	GIRLS - Current users 4 [WATER PIPE - Prevalence (%) ]
B16jjj_B16x1	GIRLS - Current users 4 [Age range]
B16jjj_B16x2	GIRLS - Current users 4 [SMOKING TOBACCO - Prevalence (%)]
B16jjj_B16x3	GIRLS - Current users 4 [SMOKELESS TOBACCO - Prevalence (%) ]
B16jjj_B16x4	GIRLS - Current users 4 [WATER PIPE - Prevalence (%) ]
B16jjjj_B16x1	GIRLS - Current users 4 [Age range]
B16jjjj_B16x2	GIRLS - Current users 4 [SMOKING TOBACCO - Prevalence (%)]
B16jjjj_B16x3	GIRLS - Current users 4 [SMOKELESS TOBACCO - Prevalence (%) ]
B16jjjj_B16x4	GIRLS - Current users 4 [WATER PIPE - Prevalence (%) ]
B16k_B16x1	TOTAL (boys and girls) - Current users 4 [Age range] 13-15 years
B16k_B16x2	TOTAL (boys and girls) - Current users 4 [SMOKING TOBACCO - Prevalence (%)]
B16k_B16x3	TOTAL (boys and girls) - Current users 4 [SMOKELESS TOBACCO - Prevalence (%) ]
B16k_B16x4	TOTAL (boys and girls) - Current users 4 [WATER PIPE - Prevalence (%) ]
B16l_B16x1	TOTAL (boys and girls) - Current users 4 [Age range]

B16l_B16x2	TOTAL (boys and girls) - Current users 4 [SMOKING TOBACCO - Prevalence (%)]
B16l_B16x3	TOTAL (boys and girls) - Current users 4 [SMOKELESS TOBACCO - Prevalence (%) ]
B16l_B16x4	TOTAL (boys and girls) - Current users 4 [WATER PIPE - Prevalence (%) ]
B16m_B16x1	TOTAL (boys and girls) - Current users 4 [Age range]
B16m_B16x2	TOTAL (boys and girls) - Current users 4 [SMOKING TOBACCO - Prevalence (%)]
B16m_B16x3	TOTAL (boys and girls) - Current users 4 [SMOKELESS TOBACCO - Prevalence (%) ]
B16m_B16x4	TOTAL (boys and girls) - Current users 4 [WATER PIPE - Prevalence (%) ]
B16n_B16x1	TOTAL (boys and girls) - Current users 4 [Age range]
B16n_B16x2	TOTAL (boys and girls) - Current users 4 [SMOKING TOBACCO - Prevalence (%)]
B16n_B16x3	TOTAL (boys and girls) - Current users 4 [SMOKELESS TOBACCO - Prevalence (%) ]
B16n_B16x4	TOTAL (boys and girls) - Current users 4 [WATER PIPE - Prevalence (%) ]
B16o_B16x1	TOTAL (boys and girls) - Current users 4 [Age range]
B16o_B16x2	TOTAL (boys and girls) - Current users 4 [SMOKING TOBACCO - Prevalence (%)]
B16o_B16x3	TOTAL (boys and girls) - Current users 4 [SMOKELESS TOBACCO - Prevalence (%) ]
B16o_B16x4	TOTAL (boys and girls) - Current users 4 [WATER PIPE - Prevalence (%)]
B1600_B16x1	TOTAL (boys and girls) - Current users 4 [Age range]
B1600_B16x2	TOTAL (boys and girls) - Current users 4 [SMOKING TOBACCO - Prevalence (%)]
B1600_B16x3	TOTAL (boys and girls) - Current users 4 [SMOKELESS TOBACCO - Prevalence (%) ]
B1600_B16x4	TOTAL (boys and girls) - Current users 4 [WATER PIPE - Prevalence (%)]

	B16000_B16x1	TOTAL (boys and girls) - Current users 4 [Age range]
	B16000_B16x2	TOTAL (boys and girls) - Current users 4 [SMOKING TOBACCO - Prevalence (%)]
	B16000_B16x3	TOTAL (boys and girls) - Current users 4 [SMOKELESS TOBACCO - Prevalence (%) ]
	B16000_B16x4	TOTAL (boys and girls) - Current users 4 [WATER PIPE - Prevalence (%) ]
	B160000_B16x	TOTAL (boys and girls) - Current users 4 [Age range]
	B160000_B16x	TOTAL (boys and girls) - Current users 4 [SMOKING TOBACCO - Prevalence (%)]
	B160000_B16x	TOTAL (boys and girls) - Current users 4 [SMOKELESS TOBACCO - Prevalence (%) ]
	B160000_B16x	TOTAL (boys and girls) - Current users 4 [WATER PIPE - Prevalence (%) ]
B161		Please indicate the tobacco products included in calculating prevalence for question B16:  Smokers of any tobacco products
B162A		
BIOZA		Please indicate the year of the data used to answer question B16: 2019
B162B		Please indicate the source of the data used to answer question B16:
DTOZD		GYTS Survey Report, 2020
B163		Please provide the definition of "current smoking/tobacco use" used to answer question
D100		B16 in the space below.
		Current smoker - the person who used a tobacco product in the last month
B164		Please provide a brief explanation of the trend in tobacco use by young persons in the past two years or since submission of your last report.
		Tobacco smoking overall prevalence among young persons of age 13-15 years old increased by 3,6% from previous GYTS Survey in 2013, among boys - by 3,8%, among girls - by 5.8%.
SQ001_SQ001		Male
	SQ001_SQ001	Prevalence (%) (please include all smoking tobacco products in prevalence data) [Prevalence (%) (please include all smoking tobacco products in prevalence data)]
	SQ001_SQ002	Prevalence (%) (please include all smoking tobacco products in prevalence data) [Average number of the most-consumed smoking tobacco product used per day]
	SQ002_SQ001	Average number of the most-consumed smoking tobacco product used per day [Prevalence (%) (please include all smoking tobacco products in prevalence data)]
	SQ002_SQ002	Average number of the most-consumed smoking tobacco product used per day [Average number of the most-consumed smoking tobacco product used per day]

	SQ003_SQ001	Occasional smokers [Prevalence (%) (please include all smoking tobacco products in prevalence data)]
	SQ003_SQ002	Occasional smokers [Average number of the most-consumed smoking tobacco product used per day]
	SQ004_SQ001	Former smokers [Prevalence (%) (please include all smoking tobacco products in prevalence data)]
	SQ004_SQ002	Former smokers [Average number of the most-consumed smoking tobacco product used per day]
	SQ005_SQ001	Never smokers [Prevalence (%) (please include all smoking tobacco products in prevalence data)]
	SQ005_SQ002	Never smokers [Average number of the most-consumed smoking tobacco product used per day]
1_1		Use of novel and emerging tobacco and nicotine products
	1_1	Age range [Age range]
		18-69
	1_2	Age range [Heated tobacco products (HTPs) - Prevalence (%)]
	4.0	3,8
	1_3	Age range [Electronic Nicotine Delivery Systems (ENDS) - Prevalence (%)]  1,2
	1_4	Age range [Electronic Non-Nicotine Delivery Systems (ENNDS) - Prevalence (%)]
	1_5	Age range [Other products - Prevalence (%)]
	2_1	Heated tobacco products (HTPs) - Prevalence (%) [Age range] 18-69
	2_2	Heated tobacco products (HTPs) - Prevalence (%) [Heated tobacco products (HTPs) - Prevalence (%)]
		1,4
	2_3	Heated tobacco products (HTPs) - Prevalence (%) [Electronic Nicotine Delivery Systems (ENDS) - Prevalence (%)]
		0,2
	2_4	Heated tobacco products (HTPs) - Prevalence (%) [Electronic Non-Nicotine Delivery

2_5	Heated tobacco products (HTPs) - Prevalence (%) [Other products - Prevalence (%)]
3_1	Electronic Nicotine Delivery Systems (ENDS) - Prevalence (%) [Age range]
	18-69
3_2	Electronic Nicotine Delivery Systems (ENDS) - Prevalence (%) [Heated tobacco products (HTPs) - Prevalence (%)]
	2,6
3_3	Electronic Nicotine Delivery Systems (ENDS) - Prevalence (%) [Electronic Nicotine Delivery Systems (ENDS) - Prevalence (%)]
	0,7
3_4	Electronic Nicotine Delivery Systems (ENDS) - Prevalence (%) [Electronic Non-Nicotine Delivery Systems (ENNDS) - Prevalence (%)]
3_5	Electronic Nicotine Delivery Systems (ENDS) - Prevalence (%) [Other products - Prevalence (%)]
4_1	Electronic Non-Nicotine Delivery Systems (ENNDS) - Prevalence (%) [Age range]
	13-15 years
4_2	Electronic Non-Nicotine Delivery Systems (ENNDS) - Prevalence (%) [Heated tobacco products (HTPs) - Prevalence (%)]
	4.9
4_3	Electronic Non-Nicotine Delivery Systems (ENNDS) - Prevalence (%) [Electronic Nicotine Delivery Systems (ENDS) - Prevalence (%)]
	16.8
4_4	Electronic Non-Nicotine Delivery Systems (ENNDS) - Prevalence (%) [Electronic Non-Nicotine Delivery Systems (ENNDS) - Prevalence (%)]
4_5	Electronic Non-Nicotine Delivery Systems (ENNDS) - Prevalence (%) [Other products - Prevalence (%)]
5.4	Otherwood acts Presidence (0) (American)
5_1	Other products - Prevalence (%) [Age range]
	13-15 years
5_2	Other products - Prevalence (%) [Heated tobacco products (HTPs) - Prevalence (%)]
	2.7
5_3	Other products - Prevalence (%) [Electronic Nicotine Delivery Systems (ENDS) - Prevalence (%)]
<u> </u>	8.4
5_4	Other products - Prevalence (%) [Electronic Non-Nicotine Delivery Systems (ENNDS) - Prevalence (%)]
5_5	Other products - Prevalence (%) [Other products - Prevalence (%)]
6_1	YOUNG PERSONS - Total (boys and girls) [Age range]

I	1	1
		13-15 years
	6_2	YOUNG PERSONS - Total (boys and girls) [Heated tobacco products (HTPs) - Prevalence (%)]
		3.9
	6_3	YOUNG PERSONS - Total (boys and girls) [Electronic Nicotine Delivery Systems (ENDS) - Prevalence (%)]
		12.7
	6_4	YOUNG PERSONS - Total (boys and girls) [Electronic Non-Nicotine Delivery Systems (ENNDS) - Prevalence (%)]
	6_5	YOUNG PERSONS - Total (boys and girls) [Other products - Prevalence (%)]
B171		Please indicate the year and source of the data used to answer question B17.
		STEPS Report on risk factors for non-communicable diseases, Republic of Moldova, 2022
B172		Please provide a brief explanation of the trends – in adults and in young persons – in the use of novel and emerging tobacco and nicotine products in the past two years or since submission of your last report.
		During last two years we monitor an increasing trend in use of novel tobacco products- HTP and e- cigarettes, mainly in adolescents and in adults in age group 18-29 years

## **B2-B9. HEALTH, SOCIAL AND ECONOMIC INDICATORS**

and 15,7 among women, also 28,3 % of students were exposed to tobacco smoke at home four in the workplace (26,2%), with more men (35,0%) exposed than women (17,2%), which considerably increases the risk of NCDs among exposed individuals.  Please indicate the year of the data used to answer question B21: 2019  B23B	<del></del>	
Please provide details in the space below (e.g. exposure by gender, at home, in the workplace, on public transport).  One in six individuals (16.5%) were exposed to second-hand smoke at home - 17.3% amor and 15.7 among women, also 28.3 % of students were exposed to tobacco smoke at home four in the workplace (26.2%), with more men (35.0%) exposed than women (17.2%), which considerably increases the risk of NCDs among exposed individuals.  B23A  Please indicate the year of the data used to answer question B21: 2019  Please indicate the source of the data used to answer question B21: GYTS Survey, 2019  B3  Tobacco-related mortality  Do you have information on tobacco-related mortality in your population? Yes  What is the estimated total number of deaths attributable to tobacco use in your population? 6000  B33  If available, please provide any additional information on mortality attributable to tob use (e.g. lung cancer, cardiovascular diseases) in your jurisdiction. In the Republic of Moldova, tobacco is the second risk factor that contributes to the total but diseases in general population: first in men and the sixth in women.  Please indicate the year of the data used to answer questions B32 and B33: 2022  B34B  Please indicate the source of the data used to answer questions B32 and B33: Source: WHO/Europe, European HFA Database, January 2023  B4  Tobacco-related costs  Do you have information on the economic burden of tobacco use in your population, the overall cost of tobacco use imposed on your society? Yes  Please provide details (e.g. direct (health care-related) and indirect costs and, if poss the method used to setimate these costs).  From 2019 to 2020 in the Republic of Moldova, the health-care expenditure related to disea caused by tobacco consumption increased by 10% from estimated at 1265 million MDL or 15% of the consolidated budget expenditures for health care to 1400 million MDL or 15% of the consolidate budget expenditures for health care. The estimates of the economic costs of related loss of p	B2	Exposure to tobacco smoke
Please provide details in the space below (e.g. exposure by gender, at home, in the workplace, on public transport).  One in six individuals (16.5%) were exposed to second-hand smoke at home - 17.3% amor and 15.7 among women, also 28.3 % of students were exposed to tobacco smoke at home four in the workplace (26.2%), with more men (35.0%) exposed than women (17.2%), which considerably increases the risk of NCDs among exposed individuals.  Please indicate the year of the data used to answer question B21: 2019  B23B  Please indicate the source of the data used to answer question B21: GYTS Survey, 2019  B3  Tobacco-related mortality  Do you have information on tobacco-related mortality in your population? Yes  What is the estimated total number of deaths attributable to tobacco use in your population? 6000  B33  If available, please provide any additional information on mortality attributable to tob use (e.g. lung cancer, cardiovascular diseases) in your jurisdiction. In the Republic of Moldova, tobacco is the second risk factor that contributes to the total budiseases in general population: first in men and the sixth in women.  B34A  Please indicate the year of the data used to answer question B32 and B33: 2022  B34B  Please indicate the source of the data used to answer questions B32 and B33: Source: WHO/Europe. European HFA Database, January 2023  B4  Tobacco-related costs  Day ou have information on the economic burden of tobacco use in your population, the overall cost of tobacco use imposed on your society? Yes  Please provide details (e.g. direct (health care-related) and indirect costs and, if poss the method used to estimate these costs). From 2019 to 2020 in the Republic of Moldova, the health-care expenditure related to disea caused by tobacco consumption increased by 10% from estimated at 1265 million MDL or 15% of the consolidated budget expenditures for health care. The estimates of the economic costs of related loss of productivity due to premature death, hospitalization and outpatient treatment smo	B21	Do you have any data on exposure to tobacco smoke in your population?
workplace, on public transport).  One in six individuals (16.5%) were exposed to second-hand smoke at home - 17.3% among and 15.7 among women, also 28.3 % of students were exposed to tobacco smoke at home four in the workplace (26.2%), with more men (35.0%) exposed than women (17.2%), which considerably increases the risk of NCDs among exposed individuals.  Please indicate the year of the data used to answer question B21:  2019  B236  Please indicate the source of the data used to answer question B21:  GYTS Survey, 2019  B3  Tobacco-related mortality  Do you have information on tobacco-related mortality in your population?  Yes  What is the estimated total number of deaths attributable to tobacco use in your population?  6000  B33  If available, please provide any additional information on mortality attributable to tob use (e.g. lung cancer, cardiovascular diseases) in your jurisdiction.  In the Republic of Moldova, tobacco is the second risk factor that contributes to the total budiseases in general population: first in men and the sixth in women.  B34A  Please indicate the year of the data used to answer question B32 and 33: 2022  B34B  Please indicate the source of the data used to answer questions B32 and B33: Source: WHO/Europe, European HFA Database, January 2023  B4  Tobacco-related costs  Do you have information on the economic burden of tobacco use in your population, the overall cost of tobacco use imposed on your society?  Yes  Please provide details (e.g. direct (health care-related) and indirect costs and, if poss the method used to estimate these costs).  From 2019 to 2020 in the Republic of Moldova, the health-care expenditure related to diseacused by tobacco consumption increased by 10% from estimated at 1256 million MDL or 15% of the consolidate budget expenditures for health care to 1400 million MDL or 15% of the consolidate budget expenditures for health care. The estimates of the economic costs of related loss of productivity due to premature death, hospitalization and outpatien treatment sm		Yes
and 15,7 among women, also 28.3% of students were exposed to lobacco smoke at home four in the workplace (26.2%), with more men (35.0%) exposed than women (17.2%), which considerably increases the risk of NCDs among exposed individuals.  Please indicate the year of the data used to answer question B21: 2019  B238	B22	
B23B Please indicate the source of the data used to answer question B21: GYTS Survey, 2019 B3 Tobacco-related mortality  B31 Do you have information on tobacco-related mortality in your population? Yes  B32 What is the estimated total number of deaths attributable to tobacco use in your population? 6000 B33 If available, please provide any additional information on mortality attributable to tob use (e.g. lung cancer, cardiovascular diseases) in your jurisdiction. In the Republic of Moldova, tobacco is the second risk factor that contributes to the total burdiseases in general population: first in men and the sixth in women.  B34A Please indicate the year of the data used to answer questions B32 and B33: 2022 B34B Please indicate the source of the data used to answer questions B32 and B33: Source: WHO/Europe, European HFA Database, January 2023  B4 Do you have information on the economic burden of tobacco use in your population, the overall cost of tobacco use imposed on your society? Yes  B42 Please provide details (e.g. direct (health care-related) and indirect costs and, if poss the method used to estimate these costs). From 2019 to 2020 in the Republic of Moldova, the health-care expenditure related to disea caused by tobacco consumption increased by 10% from estimated at 1265 million MDL or 15% of the consolidated budget expenditures for health care to 1400 million MDL or 15% of the consolidated budget expenditures for health care to 1400 million MDL or 15% of the consolidated budget expenditures for health care to 1400 million MDL or 15% of the consolidated budget expenditures for health care to 1400 million MDL or 15% of the consolidated budget expenditures for health care to 1400 million MDL or 150 or 100 or 1000 million MDL or 150 or 1000		One in six individuals (16.5%) were exposed to second-hand smoke at home - 17,3% among men and 15,7 among women, also 28.3 % of students were exposed to tobacco smoke at home. One in four in the workplace (26.2%), with more men (35.0%) exposed than women (17.2%), which considerably increases the risk of NCDs among exposed individuals.
B23B Please indicate the source of the data used to answer question B21:  GYTS Survey, 2019  Tobacco-related mortality  B31 Do you have information on tobacco-related mortality in your population?  Yes  B32 What is the estimated total number of deaths attributable to tobacco use in your population?  6000  B33 If available, please provide any additional information on mortality attributable to tob use (e.g. lung cancer, cardiovascular diseases) in your jurisdiction.  In the Republic of Moldova, tobacco is the second risk factor that contributes to the total burdiseases in general population: first in men and the sixth in women.  B34A Please indicate the year of the data used to answer question B32 and 33: 2022  B34B Please indicate the source of the data used to answer questions B32 and B33: Source: WHO/Europe, European HFA Database, January 2023  B4 Tobacco-related costs  B41 Do you have information on the economic burden of tobacco use in your population, the overall cost of tobacco use imposed on your society?  Yes  B42 Please provide details (e.g. direct (health care-related) and indirect costs and, if poss the method used to estimate these costs).  From 2019 to 2020 in the Republic of Moldova, the health-care expenditure related to disea caused by tobacco consumption increased by 10% from estimated at 1265 million MDL or 15% of the consolidated budget expenditures for health care. The estimates of the economic costs of related loss of productivity due to premature death, hospitalization and outpatient treatment smoking-related diseases also increased from 1830 million MDL or 1590 million MDL or 150 million MDL or 15	B23A	Please indicate the year of the data used to answer question B21:
B31 Do you have information on tobacco-related mortality in your population? Yes B32 What is the estimated total number of deaths attributable to tobacco use in your population? 6000 B33 If available, please provide any additional information on mortality attributable to tob use (e.g. lung cancer, cardiovascular diseases) in your jurisdiction. In the Republic of Moldova, tobacco is the second risk factor that contributes to the total but diseases in general population: first in men and the sixth in women.  B34A Please indicate the year of the data used to answer questions B32 and 33: 2022 B34B Please indicate the source of the data used to answer questions B32 and B33: Source: WHO/Europe, European HFA Database, January 2023 B4 Do you have information on the economic burden of tobacco use in your population, the overall cost of tobacco use imposed on your society? Yes B42 Please provide details (e.g. direct (health care-related) and indirect costs and, if poss the method used to estimate these costs). From 2019 to 2020 in the Republic of Moldova, the health-care expenditure related to disea caused by tobacco consumption increased by 10% from estimated at 1265 million MDL or 15% of the consolidated budget expenditures for health care. The estimates of the economic costs of related loss of productivity due to premature death, hospitalization and outpatient treatment smoking-related diseases also increased from 1830 million MDL in 2019 to 1900 million MDL or 18% of the consolidated budget expenditures for health care. The estimates of the economic costs of related loss of productivity due to premature death, hospitalization and outpatient treatment smoking-related diseases also increased from 1830 million MDL in 2019 to 1900 million MDL or 18% of the consolidated budget expenditures for health care. The estimates of the economic costs of related loss of productivity due to premature death, hospitalization and outpatient treatment smoking-related diseases also increased from 1830 million MDL in 2019 to 1900 million		2019
B31 Do you have information on tobacco-related mortality in your population? Yes B32 What is the estimated total number of deaths attributable to tobacco use in your population? 6000 B33 If available, please provide any additional information on mortality attributable to tob use (e.g. lung cancer, cardiovascular diseases) in your jurisdiction. In the Republic of Moldova, tobacco is the second risk factor that contributes to the total but diseases in general population: first in men and the sixth in women.  B34A Please indicate the year of the data used to answer question B32 and 33: 2022 B34B Please indicate the source of the data used to answer questions B32 and B33: Source: WHO/Europe, European HFA Database, January 2023 B4 Tobacco-related costs  B41 Do you have information on the economic burden of tobacco use in your population, the overall cost of tobacco use imposed on your society? Yes  B42 Please provide details (e.g. direct (health care-related) and indirect costs and, if poss the method used to estimate these costs). From 2019 to 2020 in the Republic of Moldova, the health-care expenditure related to disea caused by tobacco consumption increased by 10% from estimated at 1265 million MDL or 1 fix of the consolidated budget expenditures for health care to 1400 million MDL or 15% of the consolidated budget expenditures for health care to 1400 million MDL or 15% of the consolidated budget expenditures for health care. The estimates of the economic costs of related loss of productivity due to premature death, hospitalization and outpatient treatment smoking-related diseases also increased from 1300 million MDL or 2019 to 1900 million MDL or 15% of the consolidated budget expenditures for health care.	B23B	Please indicate the source of the data used to answer question B21:
B31 Do you have information on tobacco-related mortality in your population? Yes  B32 What is the estimated total number of deaths attributable to tobacco use in your population? 6000  B33 If available, please provide any additional information on mortality attributable to tob use (e.g. lung cancer, cardiovascular diseases) in your jurisdiction. In the Republic of Moldova, tobacco is the second risk factor that contributes to the total but diseases in general population: first in men and the sixth in women.  B34A Please indicate the year of the data used to answer question B32 and 33: 2022  B34B Please indicate the source of the data used to answer questions B32 and B33: Source: WHO/Europe, European HFA Database, January 2023  B4 Do you have information on the economic burden of tobacco use in your population, the overall cost of tobacco use imposed on your society? Yes  B42 Please provide details (e.g. direct (health care-related) and indirect costs and, if poss the method used to estimate these costs). From 2019 to 2020 in the Republic of Moldova, the health-care expenditure related to disea caused by tobacco consumption increased by 10% from estimated at 1265 million MDL or 15% of the consolidated budget expenditures for health care. The estimated at topatient treatment smoking-related diseases also increased from 1830 million MDL in 2019 to 1900 million MDL		GYTS Survey, 2019
Please indicate the year of the data used to answer question B32 and B33:  B34B Please indicate the year of the data used to answer questions B32 and B33:  Source: WHO/Europe, European HFA Database, January 2023  B41 Do you have information on the economic burden of tobacco use in your population, the overall cost of tobacco use imposed on your society?  Yes  B42 Please provide details (e.g. direct (health care-related) and indirect costs and, if poss the method used to estimate these costs).  From 2019 to 2020 in the Republic of Moldova, the health-care expenditure related to disea caused by tobacco consumption increased by 10% from estimated at 1265 million MDL or 15% of the consolidated budget expenditures for health care to 1400 inflion MDL or 15% of the consolidated budget expenditures for health care. The estimates of the economic costs of related loss of productivity due to premature death. Rospitalization and outpatient treatment smoking-related diseases also increased from 1830 million MDL or 1910 to 1900 million MDL or 1910 to 1900 million MDL or 1010 to 1900 million	В3	Tobacco-related mortality
B32  What is the estimated total number of deaths attributable to tobacco use in your population?  6000  B33  If available, please provide any additional information on mortality attributable to tob use (e.g. lung cancer, cardiovascular diseases) in your jurisdiction.  In the Republic of Moldova, tobacco is the second risk factor that contributes to the total bur diseases in general population: first in men and the sixth in women.  B34A  Please indicate the year of the data used to answer question B32 and 33: 2022  B34B  Please indicate the source of the data used to answer questions B32 and B33: Source: WHO/Europe, European HFA Database, January 2023  B4  Tobacco-related costs  B41  Do you have information on the economic burden of tobacco use in your population, the overall cost of tobacco use imposed on your society? Yes  Please provide details (e.g. direct (health care-related) and indirect costs and, if poss the method used to estimate these costs).  From 2019 to 2020 in the Republic of Moldova, the health-care expenditure related to disea caused by tobacco consumption increased by 10% from estimated at 1265 million MDL or 15% of the consolidated budget expenditures for health care. The estimates of the economic costs of trelated loss of productivity due to premature death, hospitalization and outpatient treatment smoking-related diseases also increased from 1830 million MDL in 2019 to 1900 million MDL	B31	Do you have information on tobacco-related mortality in your population?
B33 If available, please provide any additional information on mortality attributable to tob use (e.g. lung cancer, cardiovascular diseases) in your jurisdiction.  In the Republic of Moldova, tobacco is the second risk factor that contributes to the total but diseases in general population: first in men and the sixth in women.  B34A Please indicate the year of the data used to answer question B32 and 33: 2022  B34B Please indicate the source of the data used to answer questions B32 and B33: Source: WHO/Europe, European HFA Database, January 2023  B4 Tobacco-related costs  B41 Do you have information on the economic burden of tobacco use in your population, the overall cost of tobacco use imposed on your society? Yes  Please provide details (e.g., direct (health care-related) and indirect costs and, if poss the method used to estimate these costs).  From 2019 to 2020 in the Republic of Moldova, the health-care expenditure related to disease caused by tobacco consumption increased by 10% from estimated at 1265 million MDL or 15% of the consolidated budget expenditures for health care to 1400 million MDL or 15% of the consolidated budget expenditures for health care. The estimates of the economic costs of trelated loss of productivity due to premature death, hospitalization and outpatient treatment smoking-related diseases also increased from 1830 million MDL in 2019 to 1900 million MDL		Yes
B33  If available, please provide any additional information on mortality attributable to tob use (e.g. lung cancer, cardiovascular diseases) in your jurisdiction.  In the Republic of Moldova, tobacco is the second risk factor that contributes to the total but diseases in general population: first in men and the sixth in women.  B34A  Please indicate the year of the data used to answer question B32 and 33: 2022  B34B  Please indicate the source of the data used to answer questions B32 and B33: Source: WHO/Europe, European HFA Database, January 2023  B4  Tobacco-related costs  B41  Do you have information on the economic burden of tobacco use in your population, the overall cost of tobacco use imposed on your society? Yes  Please provide details (e.g. direct (health care-related) and indirect costs and, if poss the method used to estimate these costs).  From 2019 to 2020 in the Republic of Moldova, the health-care expenditure related to disea caused by tobacco consumption increased by 10% from estimated at 1265 million MDL or 15% of the consolidated budget expenditures for health care to 1400 million MDL or 15% of the consolidated budget expenditures for health care. The estimates of the economic costs of related loss of productivity due to premature death, hospitalization and outpatient treatment smoking-related diseases also increased from 1830 million MDL in 2019 to 1900 million MD.	B32	
use (e.g. lung cancer, cardiovascular diseases) in your jurisdiction.  In the Republic of Moldova, tobacco is the second risk factor that contributes to the total but diseases in general population: first in men and the sixth in women.  B34A  Please indicate the year of the data used to answer question B32 and 33:  2022  B34B  Please indicate the source of the data used to answer questions B32 and B33:  Source: WHO/Europe, European HFA Database, January 2023  B4  Tobacco-related costs  B41  Do you have information on the economic burden of tobacco use in your population, the overall cost of tobacco use imposed on your society?  Yes  Please provide details (e.g. direct (health care-related) and indirect costs and, if poss the method used to estimate these costs).  From 2019 to 2020 in the Republic of Moldova, the health-care expenditure related to disea caused by tobacco consumption increased by 10% from estimated at 1265 million MDL or 15% of the consolidated budget expenditures for health care to 1400 million MDL or 15% of the consolidated budget expenditures for health care to 1400 million MDL or 15% of the consolidated budget expenditures for health care as the estimates of the economic costs of the related loss of productivity due to premature death, hospitalization and outpatient treatment smoking-related diseases also increased from 1830 million MDL in 2019 to 1900 million MD.		6000
B34A  Please indicate the year of the data used to answer question B32 and 33: 2022  B34B  Please indicate the source of the data used to answer questions B32 and B33: Source: WHO/Europe, European HFA Database, January 2023  B4  Tobacco-related costs  Do you have information on the economic burden of tobacco use in your population, the overall cost of tobacco use imposed on your society? Yes  Please provide details (e.g. direct (health care-related) and indirect costs and, if poss the method used to estimate these costs).  From 2019 to 2020 in the Republic of Moldova, the health-care expenditure related to disea caused by tobacco consumption increased by 10% from estimated at 1265 million MDL or 15% of the consolidated budget expenditures for health care. The estimates of the economic costs of trelated loss of productivity due to premature death, hospitalization and outpatient treatment smoking-related diseases also increased from 1830 million MDL in 2019 to 1900 million MD	B33	If available, please provide any additional information on mortality attributable to tobacco use (e.g. lung cancer, cardiovascular diseases) in your jurisdiction.
B34B  Please indicate the source of the data used to answer questions B32 and B33:  Source: WHO/Europe, European HFA Database, January 2023  B4  Do you have information on the economic burden of tobacco use in your population, the overall cost of tobacco use imposed on your society?  Yes  Please provide details (e.g. direct (health care-related) and indirect costs and, if poss the method used to estimate these costs).  From 2019 to 2020 in the Republic of Moldova, the health-care expenditure related to disea caused by tobacco consumption increased by 10% from estimated at 1265 million MDL or 15% of the consolidated budget expenditures for health care to 1400 million MDL or 15% of the consolidated budget expenditures for health care. The estimates of the economic costs of the related loss of productivity due to premature death, hospitalization and outpatient treatment smoking-related diseases also increased from 1830 million MDL in 2019 to 1900 million MDL		In the Republic of Moldova, tobacco is the second risk factor that contributes to the total burden of diseases in general population: first in men and the sixth in women.
B34B  Please indicate the source of the data used to answer questions B32 and B33:  Source: WHO/Europe, European HFA Database, January 2023  B4  Tobacco-related costs  Do you have information on the economic burden of tobacco use in your population, the overall cost of tobacco use imposed on your society?  Yes  Please provide details (e.g. direct (health care-related) and indirect costs and, if poss the method used to estimate these costs).  From 2019 to 2020 in the Republic of Moldova, the health-care expenditure related to disea caused by tobacco consumption increased by 10% from estimated at 1265 million MDL or 15 the consolidated budget expenditures for health care to 1400 million MDL or 15% of the consolidated budget expenditures for health care. The estimates of the economic costs of related loss of productivity due to premature death, hospitalization and outpatient treatment smoking-related diseases also increased from 1830 million MDL in 2019 to 1900 million MD	B34A	Please indicate the year of the data used to answer question B32 and 33:
B41  Do you have information on the economic burden of tobacco use in your population, the overall cost of tobacco use imposed on your society?  Yes  Please provide details (e.g. direct (health care-related) and indirect costs and, if poss the method used to estimate these costs).  From 2019 to 2020 in the Republic of Moldova, the health-care expenditure related to disea caused by tobacco consumption increased by 10% from estimated at 1265 million MDL or 1 the consolidated budget expenditures for health care to 1400 million MDL or 15% of the consolidated budget expenditures for health care. The estimates of the economic costs of related loss of productivity due to premature death, hospitalization and outpatient treatment smoking-related diseases also increased from 1830 million MDL in 2019 to 1900 million MD		2022
B41  Do you have information on the economic burden of tobacco use in your population, the overall cost of tobacco use imposed on your society?  Yes  Please provide details (e.g. direct (health care-related) and indirect costs and, if poss the method used to estimate these costs).  From 2019 to 2020 in the Republic of Moldova, the health-care expenditure related to disea caused by tobacco consumption increased by 10% from estimated at 1265 million MDL or 1 the consolidated budget expenditures for health care to 1400 million MDL or 15% of the consolidated budget expenditures for health care . The estimates of the economic costs of the related loss of productivity due to premature death, hospitalization and outpatient treatment smoking-related diseases also increased from 1830 million MDL in 2019 to 1900 million MD.	B34B	Please indicate the source of the data used to answer questions B32 and B33:
B41  Do you have information on the economic burden of tobacco use in your population, the overall cost of tobacco use imposed on your society?  Yes  Please provide details (e.g. direct (health care-related) and indirect costs and, if poss the method used to estimate these costs).  From 2019 to 2020 in the Republic of Moldova, the health-care expenditure related to disea caused by tobacco consumption increased by 10% from estimated at 1265 million MDL or 15 the consolidated budget expenditures for health care to 1400 million MDL or 15% of the consolidated budget expenditures for health care. The estimates of the economic costs of related loss of productivity due to premature death, hospitalization and outpatient treatment smoking-related diseases also increased from 1830 million MDL in 2019 to 1900 million MD		Source: WHO/Europe, European HFA Database, January 2023
Please provide details (e.g. direct (health care-related) and indirect costs and, if poss the method used to estimate these costs).  From 2019 to 2020 in the Republic of Moldova, the health-care expenditure related to disea caused by tobacco consumption increased by 10% from estimated at 1265 million MDL or 15 the consolidated budget expenditures for health care to 1400 million MDL or 15% of the consolidated budget expenditures for health care . The estimates of the economic costs of the related loss of productivity due to premature death, hospitalization and outpatient treatment smoking-related diseases also increased from 1830 million MDL in 2019 to 1900 million MD.	B4	Tobacco-related costs
Please provide details (e.g. direct (health care-related) and indirect costs and, if poss the method used to estimate these costs).  From 2019 to 2020 in the Republic of Moldova, the health-care expenditure related to disea caused by tobacco consumption increased by 10% from estimated at 1265 million MDL or 15 the consolidated budget expenditures for health care to 1400 million MDL or 15% of the consolidated budget expenditures for health care . The estimates of the economic costs of the related loss of productivity due to premature death, hospitalization and outpatient treatment smoking-related diseases also increased from 1830 million MDL in 2019 to 1900 million MD.	B41	Do you have information on the economic burden of tobacco use in your population, e.g. the overall cost of tobacco use imposed on your society?
the method used to estimate these costs).  From 2019 to 2020 in the Republic of Moldova, the health-care expenditure related to disea caused by tobacco consumption increased by 10% from estimated at 1265 million MDL or 15 the consolidated budget expenditures for health care to 1400 million MDL or 15% of the consolidated budget expenditures for health care . The estimates of the economic costs of the related loss of productivity due to premature death, hospitalization and outpatient treatment smoking-related diseases also increased from 1830 million MDL in 2019 to 1900 million MD.		Yes
caused by tobacco consumption increased by 10% from estimated at 1265 million MDL or 1 the consolidated budget expenditures for health care to 1400 million MDL or 15% of the consolidated budget expenditures for health care . The estimates of the economic costs of trelated loss of productivity due to premature death, hospitalization and outpatient treatment smoking-related diseases also increased from 1830 million MDL in 2019 to 1900 million MD	B42	Please provide details (e.g. direct (health care-related) and indirect costs and, if possible, the method used to estimate these costs).
		consolidated budget expenditures for health care . The estimates of the economic costs of tobaccorelated loss of productivity due to premature death, hospitalization and outpatient treatment of smoking-related diseases also increased from 1830 million MDL in 2019 to 1900 million MDL in
B43A Please indicate the year of the data used to answer question B42:	B43A	Please indicate the year of the data used to answer question B42:

		2020
B43B		Please indicate the source of the data used to answer question B42:
		Experts extimations
B5		Supply of tobacco and tobacco products (with reference to Articles 6.2(b), 20.4(c), and 15.5)
B51a_B51x1		Licit supply of tobacco products
	B51a_B51x1	Smoking tobacco products [Product]
		Cigarettes 2019
	B51a_B51x2	Smoking tobacco products [Unit (e.g. pieces, tonnes)]
		pieces
	B51a_B51x3	Smoking tobacco products [Domestic production]
		800,000,000
	B51a_B51x4	Smoking tobacco products [Retail sales]
	B51a_B51x5	Smoking tobacco products [Exports]
		450,000
	B51a_B51x6	Smoking tobacco products [Imports]
		2,800,000,000
	B51b_B51x1	Smoking tobacco products [Product]
	B51b_B51x2	Smoking tobacco products [Unit (e.g. pieces, tonnes)]
	B51b_B51x3	Smoking tobacco products [Domestic production]
	B51b_B51x4	Smoking tobacco products [Retail sales]
	B51b_B51x5	Smoking tobacco products [Exports]
	B51b_B51x6	Smoking tobacco products [Imports]
	B51c_B51x1	Smoking tobacco products [Product]
	B51c_B51x2	Smoking tobacco products [Unit (e.g. pieces, tonnes)]
	B51c_B51x3	Smoking tobacco products [Domestic production]
	B51c_B51x4	Smoking tobacco products [Retail sales]

	B51c_B51x5	Smoking tobacco products [Exports]
	_	
	B51c_B51x6	Smoking tobacco products [Imports]
	B51cc_B51x1	Smoking tobacco products [Product]
	B51cc_B51x2	Smoking tobacco products [Unit (e.g. pieces, tonnes)]
	B51cc_B51x3	Smoking tobacco products [Domestic production]
	B51cc_B51x4	Smoking tobacco products [Retail sales]
	B51cc_B51x5	Smoking tobacco products [Exports]
	B51cc_B51x6	Smoking tobacco products [Imports]
	B51ccc_B51x1	Smoking tobacco products [Product]
	B51ccc_B51x2	Smoking tobacco products [Unit (e.g. pieces, tonnes)]
	B51ccc_B51x3	Smoking tobacco products [Domestic production]
	B51ccc_B51x4	Smoking tobacco products [Retail sales]
	B51ccc_B51x5	Smoking tobacco products [Exports]
	B51ccc_B51x6	Smoking tobacco products [Imports]
	B51cccc_B51x 1	Smoking tobacco products [Product]
	B51cccc_B51x 2	Smoking tobacco products [Unit (e.g. pieces, tonnes)]
	B51cccc_B51x 3	Smoking tobacco products [Domestic production]
	B51cccc_B51x 4	Smoking tobacco products [Retail sales]
	B51cccc_B51x 5	Smoking tobacco products [Exports]
	1	

B51cccc_B5	Smoking tobacco products [Imports]
B51d_B51x	Smokeless tobacco products [Product]
B51d_B51x	Smokeless tobacco products [Unit (e.g. pieces, tonnes)]
B51d_B51x	Smokeless tobacco products [Domestic production]
B51d_B51x	Smokeless tobacco products [Retail sales]
B51d_B51x	Smokeless tobacco products [Exports]
B51d_B51x	Smokeless tobacco products [Imports]
B51e_B51x	Smokeless tobacco products [Product]
B51e_B51x	Smokeless tobacco products [Unit (e.g. pieces, tonnes)]
B51e_B51x	Smokeless tobacco products [Domestic production]
B51e_B51x	Smokeless tobacco products [Retail sales]
B51e_B51x	Smokeless tobacco products [Exports]
B51e_B51x	Smokeless tobacco products [Imports]
B51f_B51x1	Smokeless tobacco products [Product] Heets 2019
B51f_B51x2	Smokeless tobacco products [Unit (e.g. pieces, tonnes)] pieces
B51f_B51x3	Smokeless tobacco products [Domestic production] 0
B51f_B51x4	Smokeless tobacco products [Retail sales]
B51f_B51x8	Smokeless tobacco products [Exports] 0
B51f_B51x6	Smokeless tobacco products [Imports] 3000,000

B51ff_B51x1	Smokeless tobacco products [Product]
B51ff_B51x2	Smokeless tobacco products [Unit (e.g. pieces, tonnes)]
B51ff_B51x3	Smokeless tobacco products [Domestic production]
B51ff_B51x4	Smokeless tobacco products [Retail sales]
B51ff_B51x5	Smokeless tobacco products [Exports]
B51ff_B51x6	Smokeless tobacco products [Imports]
B51fff_B51x1	Smokeless tobacco products [Product]
B51fff_B51x2	Smokeless tobacco products [Unit (e.g. pieces, tonnes)]
B51fff_B51x3	Smokeless tobacco products [Domestic production]
B51fff_B51x4	Smokeless tobacco products [Retail sales]
B51fff_B51x5	Smokeless tobacco products [Exports]
B51fff_B51x6	Smokeless tobacco products [Imports]
B51ffff_B51x1	Smokeless tobacco products [Product]
B51ffff_B51x2	Smokeless tobacco products [Unit (e.g. pieces, tonnes)]
B51ffff_B51x3	Smokeless tobacco products [Domestic production]
B51ffff_B51x4	Smokeless tobacco products [Retail sales]
B51ffff_B51x5	Smokeless tobacco products [Exports]
B51ffff_B51x6	Smokeless tobacco products [Imports]
B51g_B51x1	Other tobacco products [Product]
	tobacco for water pipes

B51g_B51x2	Other tobacco products [Unit (e.g. pieces, tonnes)]
	tonnes
B51g_B51x3	Other tobacco products [Domestic production]
B51g_B51x4	Other tobacco products [Retail sales]
B51g_B51x5	Other tobacco products [Exports]
B51g_B51x6	Other tobacco products [Imports]
	150
B51h_B51x1	Other tobacco products [Product]
	electronic cigarettes 2018
B51h_B51x2	Other tobacco products [Unit (e.g. pieces, tonnes)]
	pieces
B51h_B51x3	Other tobacco products [Domestic production]
B51h_B51x4	Other tobacco products [Retail sales]
B51h_B51x5	Other tobacco products [Exports]
B51h_B51x6	Other tobacco products [Imports]
	5000
B51i_B51x1	Other tobacco products [Product]
	electronic cigarettes 2019
B51i_B51x2	Other tobacco products [Unit (e.g. pieces, tonnes)]
	pieces
B51i_B51x3	Other tobacco products [Domestic production]
B51i_B51x4	Other tobacco products [Retail sales]
B51i_B51x5	Other tobacco products [Exports]
B51i_B51x6	Other tobacco products [Imports]
	6000
B51ii_B51x1	Other tobacco products [Product]
B51ii_B51x2	Other tobacco products [Unit (e.g. pieces, tonnes)]

B51ii_B51x3	Other tobacco products [Domestic production]
B51ii_B51x4	Other tobacco products [Retail sales]
B51ii_B51x5	Other tobacco products [Exports]
B51ii_B51x6	Other tobacco products [Imports]
B51iii_B51x1	Other tobacco products [Product]
B51iii_B51x2	Other tobacco products [Unit (e.g. pieces, tonnes)]
B51iii_B51x3	Other tobacco products [Domestic production]
B51iii_B51x4	Other tobacco products [Retail sales]
B51iii_B51x5	Other tobacco products [Exports]
B51iii_B51x6	Other tobacco products [Imports]
B51iiii_B51x1	Other tobacco products [Product]
B51iiii_B51x2	Other tobacco products [Unit (e.g. pieces, tonnes)]
B51iiii_B51x3	Other tobacco products [Domestic production]
B51iiii_B51x4	Other tobacco products [Retail sales]
B51iiii_B51x5	Other tobacco products [Exports]
B51iiii_B51x6	Other tobacco products [Imports]
B51j_B51x1	Tobacco leaves [Product] tobacco leaves
B51j_B51x2	Tobacco leaves [Unit (e.g. pieces, tonnes)] tonnes
B51j_B51x3	Tobacco leaves [Domestic production] 170

	B51j_B51x4	Tobacco leaves [Retail sales]
	B51j_B51x5	Tobacco leaves [Exports]
	B51j_B51x6	Tobacco leaves [Imports]
		2000
B52		Please provide information on the volumes of duty-free sales (e.g. product, unit, quantity), if available.
		none available
B53A		Please indicate the year of the data used to answer question B51 and 52:
		2022
B53B		Please indicate the source of the data used to answer questions B51 and B52:
		Custom Service reports
В6		Seizures of illicit tobacco products (with reference to Article 15.5)
B61a_B61x1		Seizures of illicit tobacco
	B61a_B61x1	Smoking tobacco products [Year]
		2016
	B61a_B61x2	Smoking tobacco products [Product]
		cigarettes
	B61a_B61x3	Smoking tobacco products [Unit (e.g. pieces, tonnes)]
	DOTA_DOTAS	
	P610 P61v4	pieces  Smalling to become anadysta FO vantity coined 1
	B61a_B61x4	Smoking tobacco products [Quantity seized ]
		4565000
	B61b_B61x1	Smoking tobacco products [Year]
		2017
	B61b_B61x2	Smoking tobacco products [Product]
		cigarettes
	B61b_B61x3	Smoking tobacco products [Unit (e.g. pieces, tonnes)]
		pieces
	B61b_B61x4	Smoking tobacco products [Quantity seized ]
		5673000
	B61c_B61x1	Smoking tobacco products [Year]
		2018
	B61c_B61x2	Smoking tobacco products [Product]
		cigarettes
	B61c_B61x3	Smoking tobacco products [Unit (e.g. pieces, tonnes)]
		pieces
L	<u> </u>	<u> </u>

	B61c_B61x4	Smoking tobacco products [Quantity seized ]
		4321000
	B61cc_B61x1	Smoking tobacco products [Year]
		2019
	B61cc_B61x2	Smoking tobacco products [Product]
	_	cigarettes
	B61cc_B61x3	Smoking tobacco products [Unit (e.g. pieces, tonnes)]
		pieces
	B61cc_B61x4	Smoking tobacco products [Quantity seized ]
		2714040
	B61ccc_B61x1	Smoking tobacco products [Year]
	B01000_B01X1	
	B61ccc_B61x2	2020 Smoking tobacco products [Product]
	BOTCCC_BOTX2	
	DOLLAR DOLLAR	cigarettes
	B61ccc_B61x3	Smoking tobacco products [Unit (e.g. pieces, tonnes)]
		pieces
	B61ccc_B61x4	Smoking tobacco products [Quantity seized ]
		2060900
	B61cccc_B61x 1	Smoking tobacco products [Year]
		2021
	B61cccc_B61x 2	Smoking tobacco products [Product]
		cigarettes
	B61cccc_B61x	Smoking tobacco products [Unit (e.g. pieces, tonnes)]
		pieces
	B61cccc_B61x	Smoking tobacco products [Quantity seized ]
	4	1360000
	B61ccccc_B61 x1	Smoking tobacco products [Year]
	X1	2022
	B61ccccc_B61	Smoking tobacco products [Product]
	x2	cigarettes
	B61ccccc_B61	Smoking tobacco products [Unit (e.g. pieces, tonnes)]
	x3	pieces
	B61ccccc_B61	Smoking tobacco products [Quantity seized ]
	x4	7600000
	B61ccccc_B6	Smoking tobacco products [Year]
	1x1	
	B61ccccc_B6	Smoking tobacco products [Product]
	1x2	
<u> </u>	<del>                                     </del>	

B61cccccc_B6 1x3	Smoking tobacco products [Unit (e.g. pieces, tonnes)]
B61cccccc_B6 1x4	Smoking tobacco products [Quantity seized ]
B61d_B61x1	Smokeless tobacco products [Year]
B61d_B61x2	Smokeless tobacco products [Product]
B61d_B61x3	Smokeless tobacco products [Unit (e.g. pieces, tonnes)]
B61d_B61x4	Smokeless tobacco products [Quantity seized ]
B61e_B61x1	Smokeless tobacco products [Year]
B61e_B61x2	Smokeless tobacco products [Product]
B61e_B61x3	Smokeless tobacco products [Unit (e.g. pieces, tonnes)]
B61e_B61x4	Smokeless tobacco products [Quantity seized ]
B61f_B61x1	Smokeless tobacco products [Year]
B61f_B61x2	Smokeless tobacco products [Product]
B61f_B61x3	Smokeless tobacco products [Unit (e.g. pieces, tonnes)]
B61f_B61x4	Smokeless tobacco products [Quantity seized ]
B61ff_B61x1	Smokeless tobacco products [Year]
B61ff_B61x2	Smokeless tobacco products [Product]
B61ff_B61x3	Smokeless tobacco products [Unit (e.g. pieces, tonnes)]
B61ff_B61x4	Smokeless tobacco products [Quantity seized ]
B61fff_B61x1	Smokeless tobacco products [Year]

B61fff_B61x2	Smokeless tobacco products [Product]
B61fff_B61x3	Smokeless tobacco products [Unit (e.g. pieces, tonnes)]
B61fff_B61x4	Smokeless tobacco products [Quantity seized ]
B61ffff_B61x1	Smokeless tobacco products [Year]
B61ffff_B61x2	Smokeless tobacco products [Product]
B61ffff_B61x3	Smokeless tobacco products [Unit (e.g. pieces, tonnes)]
B61ffff_B61x4	Smokeless tobacco products [Quantity seized ]
B61fffff_B61x1	Smokeless tobacco products [Year]
B61fffff_B61x2	Smokeless tobacco products [Product]
B61fffff_B61x3	Smokeless tobacco products [Unit (e.g. pieces, tonnes)]
B61fffff_B61x4	Smokeless tobacco products [Quantity seized ]
B61fffff_B61x1	Smokeless tobacco products [Year]
B61fffff_B61x2	Smokeless tobacco products [Product]
B61ffffff_B61x3	Smokeless tobacco products [Unit (e.g. pieces, tonnes)]
B61ffffff_B61x4	Smokeless tobacco products [Quantity seized ]
B61g_B61x1	Other tobacco products [Year]
B61g_B61x2	Other tobacco products [Product]
B61g_B61x3	Other tobacco products [Unit (e.g. pieces, tonnes)]
B61g_B61x4	Other tobacco products [Quantity seized ]

B61h_B61x1	Other tobacco products [Year]
B61h_B61x2	Other tobacco products [Product]
B61h_B61x3	Other tobacco products [Unit (e.g. pieces, tonnes)]
B61h_B61x4	Other tobacco products [Quantity seized ]
B61i_B61x1	Other tobacco products [Year]
B61i_B61x2	Other tobacco products [Product]
B61i_B61x3	Other tobacco products [Unit (e.g. pieces, tonnes)]
B61i_B61x4	Other tobacco products [Quantity seized ]
B61ii_B61x1	Other tobacco products [Year]
B61ii_B61x2	Other tobacco products [Product]
B61ii_B61x3	Other tobacco products [Unit (e.g. pieces, tonnes)]
B61ii_B61x4	Other tobacco products [Quantity seized ]
B61iii_B61x1	Other tobacco products [Year]
B61iii_B61x2	Other tobacco products [Product]
B61iii_B61x3	Other tobacco products [Unit (e.g. pieces, tonnes)]
B61iii_B61x4	Other tobacco products [Quantity seized ]
B61iiii_B61x1	Other tobacco products [Year]
B61iiii_B61x2	Other tobacco products [Product]
B61iiii_B61x3	Other tobacco products [Unit (e.g. pieces, tonnes)]

	B61iiii_B61x4	Other tobacco products [Quantity seized ]
	B61iiiii_B61x1	Other tobacco products [Year]
	B61iiiii_B61x2	Other tobacco products [Product]
	B61iiiii_B61x3	Other tobacco products [Unit (e.g. pieces, tonnes)]
	B61iiiii_B61x4	Other tobacco products [Quantity seized ]
	B61iiiii_B61x1	Other tobacco products [Year]
	B61iiiiii_B61x2	Other tobacco products [Product]
	B61iiiiii_B61x3	Other tobacco products [Unit (e.g. pieces, tonnes)]
	B61iiiiii_B61x4	Other tobacco products [Quantity seized ]
B62		Do you have any information on the percentage of illicit tobacco products on the national tobacco market?
		Yes
B63		What percentage of the national tobacco market do illicit tobacco products constitute? (%) 4.3
B64		What is the trend over the past two years or since submission of your last report in the percentage of illicit tobacco products in relation to the national tobacco market?  remain unchanged.
B65		Please provide any further information on illicit tobacco products.
B66		Please indicate the source of the data used to answer questions in section B6:  Custom Service reports
B7		Tobacco-growing
B71		Is there any tobacco-growing in your jurisdiction? Yes
B72		Please provide information on the number of workers involved in tobacco-growing. If available, please provide this figure broken down by gender.
B73		200 persons  Please provide, if available, the share of the value of tobacco leaf production in the national gross domestic product.
		The share of land for tobacco growing was 200 hectars in 2019, decreased by 20% compared with 2019

P=		
B74A		Please indicate the year of the data used to answer questions in section B7:
		2022
B74B		Please indicate the source of the data used to answer questions in section B7:
		Information provided by Ministry of Agriculture and Food Industry
B8		Taxation of tobacco products (with reference to Articles 6.2(a) and 6.3)
B81		What proportion of the retail price of the most popular price category of tobacco product consists of taxes (e.g. sum of excise, sales and import duties (if applicable) and value added tax/goods and services tax (VAT/GST))?
		57%
SQ001		How are the excise taxes levied (what types of taxes are levied)?
	SQ001	Specific tax only
	SQ002	Ad valorem tax only
	SQ003	Combination of specific and ad valorem taxes
		Yes
	SQ004	More complex structure (please explain below)
B82a		If a more complex structure of taxes (please explain):
B83a_B83x1		If available, please provide details on the rates of taxation for tobacco products at all levels of Government and be as specific as possible (specify the type of tax, e.g. VAT, sales, import duties)
1		
	B83a B83x1	Smoking tobacco products [Product]
	B83a_B83x1	Smoking tobacco products [Product] all types cigarettes 2020
		all types cigarettes 2020
	B83a_B83x1 B83a_B83x2	all types cigarettes 2020  Smoking tobacco products [Type of tax]
	B83a_B83x2	all types cigarettes 2020  Smoking tobacco products [Type of tax]  Specific tax
		all types cigarettes 2020  Smoking tobacco products [Type of tax]  Specific tax  Smoking tobacco products [Rate or amount]
	B83a_B83x2 B83a_B83x3	all types cigarettes 2020  Smoking tobacco products [Type of tax]  Specific tax  Smoking tobacco products [Rate or amount]  1198 MDL per 1000
	B83a_B83x2	all types cigarettes 2020  Smoking tobacco products [Type of tax]  Specific tax  Smoking tobacco products [Rate or amount]
	B83a_B83x2 B83a_B83x3	all types cigarettes 2020  Smoking tobacco products [Type of tax]  Specific tax  Smoking tobacco products [Rate or amount]  1198 MDL per 1000
	B83a_B83x2 B83a_B83x3 B83a_B83x4	all types cigarettes 2020  Smoking tobacco products [Type of tax]  Specific tax  Smoking tobacco products [Rate or amount]  1198 MDL per 1000  Smoking tobacco products [Base of tax5]
	B83a_B83x2 B83a_B83x3 B83a_B83x4	all types cigarettes 2020  Smoking tobacco products [Type of tax]  Specific tax  Smoking tobacco products [Rate or amount]  1198 MDL per 1000  Smoking tobacco products [Base of tax5]  Smoking tobacco products [Product]
	B83a_B83x2  B83a_B83x3  B83a_B83x4  B83b_B83x1	all types cigarettes 2020  Smoking tobacco products [Type of tax]  Specific tax  Smoking tobacco products [Rate or amount]  1198 MDL per 1000  Smoking tobacco products [Base of tax5]  Smoking tobacco products [Product]  all types cigarettes 2020
	B83a_B83x2  B83a_B83x3  B83a_B83x4  B83b_B83x1	all types cigarettes 2020  Smoking tobacco products [Type of tax]  Specific tax  Smoking tobacco products [Rate or amount]  1198 MDL per 1000  Smoking tobacco products [Base of tax5]  Smoking tobacco products [Product]  all types cigarettes 2020  Smoking tobacco products [Type of tax]

B83b_B83x4	Smoking tobacco products [Base of tax5]
B83c_B83x1	Smoking tobacco products [Product]
B83c_B83x2	Smoking tobacco products [Type of tax]
B83c_B83x3	Smoking tobacco products [Rate or amount]
B83c_B83x4	Smoking tobacco products [Base of tax5]
B83cc_B83x1	Smoking tobacco products [Product]
B83cc_B83x2	Smoking tobacco products [Type of tax]
B83cc_B83x3	Smoking tobacco products [Rate or amount]
B83cc_B83x4	Smoking tobacco products [Base of tax5]
B83ccc_B83x1	Smoking tobacco products [Product]
B83ccc_B83x2	Smoking tobacco products [Type of tax]
B83ccc_B83x3	Smoking tobacco products [Rate or amount]
B83ccc_B83x4	Smoking tobacco products [Base of tax5]
B83cccc_B83x 1	Smoking tobacco products [Product]
B83cccc_B83x 2	Smoking tobacco products [Type of tax]
B83cccc_B83x 3	Smoking tobacco products [Rate or amount]
B83cccc_B83x 4	Smoking tobacco products [Base of tax5]
B83ccccc_B83 x1	Smoking tobacco products [Product]
B83ccccc_B83 x2	Smoking tobacco products [Type of tax]

B83cccc_B83 x3	Smoking tobacco products [Rate or amount]
B83cccc_B83 x4	Smoking tobacco products [Base of tax5]
B83ccccc_B8 3x1	Smoking tobacco products [Product]
B83ccccc_B8 3x2	Smoking tobacco products [Type of tax]
B83ccccc_B8 3x3	Smoking tobacco products [Rate or amount]
B83ccccc_B8 3x4	Smoking tobacco products [Base of tax5]
B83d_B83x1	Smokeless tobacco products [Product]
B83d_B83x2	Smokeless tobacco products [Type of tax]
B83d_B83x3	Smokeless tobacco products [Rate or amount]
B83d_B83x4	Smokeless tobacco products [Base of tax5]
B83e_B83x1	Smokeless tobacco products [Product]
B83e_B83x2	Smokeless tobacco products [Type of tax]
B83e_B83x3	Smokeless tobacco products [Rate or amount]
B83e_B83x4	Smokeless tobacco products [Base of tax5]
B83f_B83x1	Smokeless tobacco products [Product]
B83f_B83x2	Smokeless tobacco products [Type of tax]
B83f_B83x3	Smokeless tobacco products [Rate or amount]
B83f_B83x4	Smokeless tobacco products [Base of tax5]
B83ff_B83x1	Smokeless tobacco products [Product]

B83ff_B83x2	Smokeless tobacco products [Type of tax]
B83ff_B83x3	Smokeless tobacco products [Rate or amount]
B83ff_B83x4	Smokeless tobacco products [Base of tax5]
B83fff_B83x1	Smokeless tobacco products [Product]
B83fff_B83x2	Smokeless tobacco products [Type of tax]
B83fff_B83x3	Smokeless tobacco products [Rate or amount]
B83fff_B83x4	Smokeless tobacco products [Base of tax5]
B83ffff_B83x1	Smokeless tobacco products [Product]
B83ffff_B83x2	Smokeless tobacco products [Type of tax]
B83ffff_B83x3	Smokeless tobacco products [Rate or amount]
B83ffff_B83x4	Smokeless tobacco products [Base of tax5]
B83fffff_B83x1	Smokeless tobacco products [Product]
B83fffff_B83x2	Smokeless tobacco products [Type of tax]
B83fffff_B83x3	Smokeless tobacco products [Rate or amount]
B83fffff_B83x4	Smokeless tobacco products [Base of tax5]
B83ffffff_B83x1	Smokeless tobacco products [Product]
B83ffffff_B83x2	Smokeless tobacco products [Type of tax]
B83ffffff_B83x3	Smokeless tobacco products [Rate or amount]
B83ffffff_B83x4	Smokeless tobacco products [Base of tax5]

B83g_B83x1	Other tobacco products [Product]
B83g_B83x2	Other tobacco products [Type of tax]
B83g_B83x3	Other tobacco products [Rate or amount]
B83g_B83x4	Other tobacco products [Base of tax5]
B83h_B83x1	Other tobacco products [Product]
B83h_B83x2	Other tobacco products [Type of tax]
B83h_B83x3	Other tobacco products [Rate or amount]
B83h_B83x4	Other tobacco products [Base of tax5]
B83i_B83x1	Other tobacco products [Product]
B83i_B83x2	Other tobacco products [Type of tax]
B83i_B83x3	Other tobacco products [Rate or amount]
B83i_B83x4	Other tobacco products [Base of tax5]
B83ii_B83x1	Other tobacco products [Product]
B83ii_B83x2	Other tobacco products [Type of tax]
B83ii_B83x3	Other tobacco products [Rate or amount]
B83ii_B83x4	Other tobacco products [Base of tax5]
B83iii_B83x1	Other tobacco products [Product]
B83iii_B83x2	Other tobacco products [Type of tax]
B83iii_B83x3	Other tobacco products [Rate or amount]

	B83iii_B83x4	Other tobacco products [Base of tax5]
	B83iiii_B83x1	Other tobacco products [Product]
	B83iiii_B83x2	Other tobacco products [Type of tax]
	B83iiii_B83x3	Other tobacco products [Rate or amount]
	B83iiii_B83x4	Other tobacco products [Base of tax5]
	B83iiiii_B83x1	Other tobacco products [Product]
	B83iiiii_B83x2	Other tobacco products [Type of tax]
	B83iiiii_B83x3	Other tobacco products [Rate or amount]
	B83iiiii_B83x4	Other tobacco products [Base of tax5]
	B83iiiii_B83x1	Other tobacco products [Product]
	B83iiiii_B83x2	Other tobacco products [Type of tax]
	B83iiiii_B83x3	Other tobacco products [Rate or amount]
	B83iiiii_B83x4	Other tobacco products [Base of tax5]
B84		Please briefly describe the trends in taxation for tobacco products in the past two years or since submission of your last report in your jurisdiction.
		During last two years tobacco taxes increase by 30% for filtered cigarettes and taxes for non-filtered cigarettes became equal as for filtered cigarettes
B85		Do you earmark any percentage of your taxation income for funding any national plan or strategy on tobacco control in your jurisdiction?
		No
B86		Please provide details in the space below.
B87A		Please indicate the year of the data used to answer questions B81 to B86: 2020
B87B		Please indicate the source of the data used to answer questions B81 to B86:
B9		Price of tobacco products (with reference to Articles 6.2(a))

1_SQ001		Domestic Please provide the retail prices of the three most widely sold brands of domestic
		tobacco products at the most widely used point of sale in your capital city.
	1_SQ001	Smoking tobacco products [Name of the most widely sold brand]
		Temp
	1_SQ002	Smoking tobacco products [Number of units or amount per package]
		20 cigarettes
	1_SQ003	Smoking tobacco products [Retail price]
		35
	1_SQ004	Smoking tobacco products [Currency]
		MDL
	2_SQ001	Smoking tobacco products [Name of the most widely sold brand]
		Doina soft
	2_SQ002	Smoking tobacco products [Number of units or amount per package]
		20 cigarettes
	2_SQ003	Smoking tobacco products [Retail price]
		38
	2_SQ004	Smoking tobacco products [Currency]
		MDL
	3_SQ001	Smoking tobacco products [Name of the most widely sold brand]
		Astru
	3_SQ002	Smoking tobacco products [Number of units or amount per package]
		20 cigarettes
	3_SQ003	Smoking tobacco products [Retail price]
		35
	3_SQ004	Smoking tobacco products [Currency]
		MDL
	7_SQ001	Smokeless tobacco products [Name of the most widely sold brand]
	7_SQ002	Smokeless tobacco products [Number of units or amount per package]
	7_SQ003	Smokeless tobacco products [Retail price]
		process process process process
	7_SQ004	Smokeless tobacco products [Currency]
	0004	Singlification formation formation formation formation for the state of the state o
	8_SQ001	Smokeless tobacco products [Name of the most widely sold brand]

8_SQ002	Smokeless tobacco products [Number of units or amount per package]
8_SQ003	Smokeless tobacco products [Retail price]
8_SQ004	Smokeless tobacco products [Currency]
9_SQ001	Smokeless tobacco products [Name of the most widely sold brand]
9_SQ002	Smokeless tobacco products [Number of units or amount per package]
9_SQ003	Smokeless tobacco products [Retail price]
9_SQ004	Smokeless tobacco products [Currency]
13_SQ001	Other tobacco products [Name of the most widely sold brand]
13_SQ002	Other tobacco products [Number of units or amount per package]
13_SQ003	Other tobacco products [Retail price]
13_SQ004	Other tobacco products [Currency]
14_SQ001	Other tobacco products [Name of the most widely sold brand]
14_SQ002	Other tobacco products [Number of units or amount per package]
14_SQ003	Other tobacco products [Retail price]
14_SQ004	Other tobacco products [Currency]
15_SQ001	Other tobacco products [Name of the most widely sold brand]
15_SQ002	Other tobacco products [Number of units or amount per package]
15_SQ003	Other tobacco products [Retail price]
15_SQ004	Other tobacco products [Currency]

1_S0001   Smoking tobacco products [Name of the most widely sold brand]   Red&White Special Super Slims   1_S0002   Smoking tobacco products [Number of units or amount per package]   20 cigarettes   Smoking tobacco products [Retail price]   40   1_S0004   Smoking tobacco products [Currency]   MDL   2_S0001   Smoking tobacco products [Name of the most widely sold brand]   Winston   2_S0002   Smoking tobacco products [Number of units or amount per package]   20 cigarettes   2_S0003   Smoking tobacco products [Retail price]   42   2_S0004   Smoking tobacco products [Currency]   MDL   3_S0001   Smoking tobacco products [Name of the most widely sold brand]   Marlboro (Gold)   3_S0002   Smoking tobacco products [Number of units or amount per package]   20 cigarettes   3_S0003   Smoking tobacco products [Retail price]   45   3_S0004   Smoking tobacco products [Retail price]   45   3_S0004   Smoking tobacco products [Currency]   MDL   7_S0001   Smokeless tobacco products [Number of units or amount per package]   7_S0002   Smokeless tobacco products [Number of units or amount per package]   7_S0003   Smokeless tobacco products [Number of units or amount per package]   7_S0003   Smokeless tobacco products [Number of units or amount per package]   7_S0000   Smokeless tobacco products [Number of units or amount per package]   7_S0000   Smokeless tobacco products [Number of units or amount per package]   7_S0000   Smokeless tobacco products [Retail price]   7_S0000   Smokeless tobacco product	imported
1_SQ002 Smoking tobacco products [Number of units or amount per package] 20 cigarettes  1_SQ003 Smoking tobacco products [Retail price] 40  1_SQ004 Smoking tobacco products [Currency] MDL  2_SQ001 Smoking tobacco products [Name of the most widely sold brand] Winston  2_SQ002 Smoking tobacco products [Number of units or amount per package] 20 cigarettes  2_SQ003 Smoking tobacco products [Retail price] 42  2_SQ004 Smoking tobacco products [Currency] MDL  3_SQ001 Smoking tobacco products [Name of the most widely sold brand] Marlboro (Gold)  3_SQ002 Smoking tobacco products [Number of units or amount per package] 20 cigarettes  3_SQ003 Smoking tobacco products [Retail price] 45  3_SQ004 Smoking tobacco products [Retail price] 45  3_SQ004 Smoking tobacco products [Retail price] 45  3_SQ004 Smoking tobacco products [Currency] MDL  7_SQ001 Smokeless tobacco products [Name of the most widely sold brand]  7_SQ001 Smokeless tobacco products [Number of units or amount per package]	
20 cigarettes  1_SQ003 Smoking tobacco products [Retail price] 40  1_SQ004 Smoking tobacco products [Currency] MDL  2_SQ001 Smoking tobacco products [Name of the most widely sold brand] Winston  2_SQ002 Smoking tobacco products [Number of units or amount per package] 20 cigarettes  2_SQ003 Smoking tobacco products [Retail price] 42  2_SQ004 Smoking tobacco products [Currency] MDL  3_SQ001 Smoking tobacco products [Name of the most widely sold brand] Marlboro (Gold)  3_SQ002 Smoking tobacco products [Number of units or amount per package] 20 cigarettes  3_SQ003 Smoking tobacco products [Retail price] 45  3_SQ004 Smoking tobacco products [Retail price] 45  3_SQ004 Smoking tobacco products [Currency] MDL  7_SQ001 Smokeless tobacco products [Name of the most widely sold brand]  7_SQ002 Smokeless tobacco products [Number of units or amount per package]	
1_SQ003   Smoking tobacco products [Retail price]   40	
40  1_SQ004 Smoking tobacco products [Currency]  MDL  2_SQ001 Smoking tobacco products [Name of the most widely sold brand]  Winston  2_SQ002 Smoking tobacco products [Number of units or amount per package]  20 cigarettes  2_SQ003 Smoking tobacco products [Retail price]  42  2_SQ004 Smoking tobacco products [Currency]  MDL  3_SQ001 Smoking tobacco products [Name of the most widely sold brand]  Marlboro (Gold)  3_SQ002 Smoking tobacco products [Number of units or amount per package]  20 cigarettes  3_SQ003 Smoking tobacco products [Retail price]  45  3_SQ004 Smoking tobacco products [Currency]  MDL  7_SQ001 Smokeless tobacco products [Name of the most widely sold brand]  7_SQ002 Smokeless tobacco products [Name of the most widely sold brand]  7_SQ002 Smokeless tobacco products [Number of units or amount per package]	
1_SQ004   Smoking tobacco products [Currency]	
MDL  2_SQ001 Smoking tobacco products [Name of the most widely sold brand] Winston  2_SQ002 Smoking tobacco products [Number of units or amount per package] 20 cigarettes  2_SQ003 Smoking tobacco products [Retail price] 42  2_SQ004 Smoking tobacco products [Currency] MDL  3_SQ001 Smoking tobacco products [Name of the most widely sold brand] Mariboro (Gold)  3_SQ002 Smoking tobacco products [Number of units or amount per package] 20 cigarettes  3_SQ003 Smoking tobacco products [Retail price] 45  3_SQ004 Smoking tobacco products [Currency] MDL  7_SQ001 Smokeless tobacco products [Name of the most widely sold brand]  7_SQ002 Smokeless tobacco products [Name of the most widely sold brand]	
Smoking tobacco products [Name of the most widely sold brand] Winston  2_SQ002 Smoking tobacco products [Number of units or amount per package] 20 cigarettes  2_SQ003 Smoking tobacco products [Retail price] 42  2_SQ004 Smoking tobacco products [Currency] MDL  3_SQ001 Smoking tobacco products [Name of the most widely sold brand] Marlboro (Gold)  3_SQ002 Smoking tobacco products [Number of units or amount per package] 20 cigarettes  3_SQ003 Smoking tobacco products [Retail price] 45  3_SQ004 Smoking tobacco products [Currency] MDL  7_SQ001 Smokeless tobacco products [Name of the most widely sold brand]  7_SQ002 Smokeless tobacco products [Name of the most widely sold brand]	
Winston  2_SQ002 Smoking tobacco products [Number of units or amount per package] 20 cigarettes  2_SQ003 Smoking tobacco products [Retail price] 42  2_SQ004 Smoking tobacco products [Currency] MDL  3_SQ001 Smoking tobacco products [Name of the most widely sold brand] Marlboro (Gold)  3_SQ002 Smoking tobacco products [Number of units or amount per package] 20 cigarettes  3_SQ003 Smoking tobacco products [Retail price] 45  3_SQ004 Smoking tobacco products [Currency] MDL  7_SQ001 Smokeless tobacco products [Name of the most widely sold brand]  7_SQ002 Smokeless tobacco products [Name of the most widely sold brand]	
2_SQ002 Smoking tobacco products [Number of units or amount per package] 20 cigarettes  2_SQ003 Smoking tobacco products [Retail price] 42  2_SQ004 Smoking tobacco products [Currency] MDL  3_SQ001 Smoking tobacco products [Name of the most widely sold brand] Marlboro (Gold)  3_SQ002 Smoking tobacco products [Number of units or amount per package] 20 cigarettes  3_SQ003 Smoking tobacco products [Retail price] 45  3_SQ004 Smoking tobacco products [Currency] MDL  7_SQ001 Smokeless tobacco products [Name of the most widely sold brand]  7_SQ002 Smokeless tobacco products [Name of the most widely sold brand]	
20 cigarettes  2_SQ003 Smoking tobacco products [Retail price] 42  2_SQ004 Smoking tobacco products [Currency] MDL  3_SQ001 Smoking tobacco products [Name of the most widely sold brand] Marlboro (Gold)  3_SQ002 Smoking tobacco products [Number of units or amount per package] 20 cigarettes  3_SQ003 Smoking tobacco products [Retail price] 45  3_SQ004 Smoking tobacco products [Currency] MDL  7_SQ001 Smokeless tobacco products [Name of the most widely sold brand]  7_SQ002 Smokeless tobacco products [Name of the most widely sold brand]	
2_SQ003 Smoking tobacco products [Retail price] 42  2_SQ004 Smoking tobacco products [Currency] MDL  3_SQ001 Smoking tobacco products [Name of the most widely sold brand] Marlboro (Gold)  3_SQ002 Smoking tobacco products [Number of units or amount per package] 20 cigarettes  3_SQ003 Smoking tobacco products [Retail price] 45  3_SQ004 Smoking tobacco products [Currency] MDL  7_SQ001 Smokeless tobacco products [Name of the most widely sold brand]  7_SQ002 Smokeless tobacco products [Number of units or amount per package]	
2_SQ004 Smoking tobacco products [Currency]  MDL  3_SQ001 Smoking tobacco products [Name of the most widely sold brand]  Marlboro (Gold)  3_SQ002 Smoking tobacco products [Number of units or amount per package]  20 cigarettes  3_SQ003 Smoking tobacco products [Retail price]  45  3_SQ004 Smoking tobacco products [Currency]  MDL  7_SQ001 Smokeless tobacco products [Name of the most widely sold brand]  7_SQ002 Smokeless tobacco products [Number of units or amount per package]	
Smoking tobacco products [Currency]   MDL	
MDL  3_SQ001 Smoking tobacco products [Name of the most widely sold brand]  Marlboro (Gold)  3_SQ002 Smoking tobacco products [Number of units or amount per package]  20 cigarettes  3_SQ003 Smoking tobacco products [Retail price]  45  3_SQ004 Smoking tobacco products [Currency]  MDL  7_SQ001 Smokeless tobacco products [Name of the most widely sold brand]  7_SQ002 Smokeless tobacco products [Number of units or amount per package]	
Smoking tobacco products [Name of the most widely sold brand]  Marlboro (Gold)  3_SQ002 Smoking tobacco products [Number of units or amount per package] 20 cigarettes  3_SQ003 Smoking tobacco products [Retail price] 45  3_SQ004 Smoking tobacco products [Currency] MDL  7_SQ001 Smokeless tobacco products [Name of the most widely sold brand]  7_SQ002 Smokeless tobacco products [Number of units or amount per package]	
Marlboro (Gold)  3_SQ002 Smoking tobacco products [Number of units or amount per package] 20 cigarettes  3_SQ003 Smoking tobacco products [Retail price] 45  3_SQ004 Smoking tobacco products [Currency] MDL  7_SQ001 Smokeless tobacco products [Name of the most widely sold brand]  7_SQ002 Smokeless tobacco products [Number of units or amount per package]	
Smoking tobacco products [Number of units or amount per package] 20 cigarettes  3_SQ003 Smoking tobacco products [Retail price] 45  3_SQ004 Smoking tobacco products [Currency] MDL  7_SQ001 Smokeless tobacco products [Name of the most widely sold brand]  7_SQ002 Smokeless tobacco products [Number of units or amount per package]	
20 cigarettes  3_SQ003 Smoking tobacco products [Retail price]  45  3_SQ004 Smoking tobacco products [Currency]  MDL  7_SQ001 Smokeless tobacco products [Name of the most widely sold brand]  7_SQ002 Smokeless tobacco products [Number of units or amount per package]	
Smoking tobacco products [Retail price]  45  3_SQ004 Smoking tobacco products [Currency]  MDL  7_SQ001 Smokeless tobacco products [Name of the most widely sold brand]  7_SQ002 Smokeless tobacco products [Number of units or amount per package]	
3_SQ004 Smoking tobacco products [Currency]  MDL  7_SQ001 Smokeless tobacco products [Name of the most widely sold brand]  7_SQ002 Smokeless tobacco products [Number of units or amount per package]	
3_SQ004 Smoking tobacco products [Currency] MDL  7_SQ001 Smokeless tobacco products [Name of the most widely sold brand]  7_SQ002 Smokeless tobacco products [Number of units or amount per package]	
MDL  7_SQ001 Smokeless tobacco products [Name of the most widely sold brand]  7_SQ002 Smokeless tobacco products [Number of units or amount per package]	
7_SQ001 Smokeless tobacco products [Name of the most widely sold brand]  7_SQ002 Smokeless tobacco products [Number of units or amount per package]	
7_SQ002 Smokeless tobacco products [Number of units or amount per package]	
7_SQ003 Smokeless tobacco products [Retail price]	
7_SQ004 Smokeless tobacco products [Currency]	
8_SQ001 Smokeless tobacco products [Name of the most widely sold brand]	
8_SQ002 Smokeless tobacco products [Number of units or amount per package]	

	8_SQ003	Smokeless tobacco products [Retail price]
	8_SQ004	Smokeless tobacco products [Currency]
	9_SQ001	Smokeless tobacco products [Name of the most widely sold brand]
	9_SQ002	Smokeless tobacco products [Number of units or amount per package]
	9_SQ003	Smokeless tobacco products [Retail price]
	9_SQ004	Smokeless tobacco products [Currency]
	13_SQ001	Other tobacco products [Name of the most widely sold brand]
	13_SQ002	Other tobacco products [Number of units or amount per package]
	13_SQ003	Other tobacco products [Retail price]
	13_SQ004	Other tobacco products [Currency]
	14_SQ001	Other tobacco products [Name of the most widely sold brand]
	14_SQ002	Other tobacco products [Number of units or amount per package]
	14_SQ003	Other tobacco products [Retail price]
	14_SQ004	Other tobacco products [Currency]
	15_SQ001	Other tobacco products [Name of the most widely sold brand]
	15_SQ002	Other tobacco products [Number of units or amount per package]
	15_SQ003	Other tobacco products [Retail price]
	15_SQ004	Other tobacco products [Currency]
B92A		Please indicate the year of the data used to answer question B91: 2020

B92B	Please indicate the source of the data used to answer question B91:
	Expert groups reports
B93	Please briefly describe the trend in the prices of tobacco products in the past two years or since submission of your last report in your jurisdiction.
	Prices of cigarettes and other tobacco products in the past two years increase by more than 70%, introduced from 2023 minimum price for cigarette pack is 35 MDL (2 USD)

# **C1. GENERAL OBLIGATIONS**

C1		With reference to Article 5
C111		Have you developed and implemented comprehensive multisectoral national tobacco control strategies, plans and programmes in accordance with the Convention?
		Yes
C112		Have you partially developed and implemented tobacco control strategies by including tobacco control in national health, public health or health promotion strategies, plans and programmes?
		N/A
C113		Is any aspect of tobacco control that is referred to in the Convention included in any national strategy, plan or programme?
		N/A
C114a		Have you established or reinforced and financed:
	C114a	a focal point for tobacco control?
		Yes
	C114b	a tobacco control unit?
		Yes
	C114c	a national coordinating mechanism for tobacco control?
		Yes
C115		Please provide details (e.g. the nature of the national coordinating mechanism, the institution to which the focal point for tobacco control or the tobacco control unit belongs)
		By the Government decision #1015 of 23.11.2017 which adopt second National Program on Tobacco Control for 2017-2021 years, was established National Coordination Council on Tobacco Control, with 17 members, which are representing all relevant institutions and is chaired by the deputy Prime-Minister. With adoption in 2015 a new Tobacco Control Law, the Council has a permanent status and is regulated by the Law. The national focal point for tobacco control and the tobacco control unit belongs to the National Agency for Public Health
C116		Please provide a brief description of the progress made in implementing Article 5.1 and 5.3 (General obligations) in the past two years or since submission of your last report.
		Developed third National Program on Tobacco Control for 2023-2027 years, which should be approved soon by the Government.
C117		If you have any other relevant information pertaining to but not covered in this section, please provide details in the space below.
C12		Protection of public health policies with respect to tobacco control from commercial and other vested interests of the tobacco industry Have you adopted and implemented, where appropriate, legislative, executive, administrative or other measures or have you implemented, where appropriate, programmes on any of the following:
C121		protecting public health policies with respect to tobacco control from commercial and other vested interests of the tobacco industry?
		Yes
C122		ensuring that the public has access, in accordance with Article 12(c), to a wide range of information on tobacco industry activities relevant to the objectives of the Convention, suc as in a public repository?

	Yes
C123	If you answered "Yes" to any of the questions under C121 or C122, please provide details in the space below (specifically, please refer, if relevant, to whether your government or any of its departments 1) have raised awareness on tobacco industry tactics and the need to prevent interference by the tobacco industry with decision making; 2) have avoided entering into any partnerships or voluntary agreements with the tobacco industry; 3) have established any measures to limit interaction of public officials with the tobacco industry, including in the form of a code of conduct; 4) have not granted any incentives, privileges, benefits or preferential tax exemptions to the tobacco industry to establish or run their business; etc.).
	The new Tobacco Control Law adopted in 2015 contain provisions for protecting public health policies with respect to tobacco control from commercial and other vested interests of the tobacco industry and to exclude conflict of interest for public servants.
C124	Please provide a brief description of the progress made in implementing Article 5.3 in the past two years or since submission of your last report.
C125	Have you utilized the "Guidelines for implementation of Article 5.3 of the WHO FCTC" when developing or implementing policies in this area?  Yes
C126	Please provide details in the space below or refer to section I of the additional questionnaire. Response to this question or to the additional questionnaire is voluntary. https://extranet.who.int/dataformv3/index.php/862235?token={TOKEN}⟨=e n
C127	If you have any other relevant information pertaining to but not covered in this section, please provide details in the space below.

# C2. MEASURES RELATING TO THE REDUCTION OF DEMAND FOR TOBACCO

C2		With reference to Articles 6–14
C21		Price and tax measures to reduce the demand for tobacco Have you adopted and implemented, where appropriate, legislative, executive, administrative or other measures or have you implemented, where appropriate, programmes on any of the following:
C211		tax policies and, where appropriate, price policies on tobacco products so as to contribute to the health objectives aimed at reducing tobacco consumption?
		Yes
C212		prohibiting or restricting, as appropriate, sales to international travellers of tax- and duty-free tobacco products?
		Yes
C213		prohibiting or restricting, as appropriate, imports by international travellers of tax- and duty-free tobacco products?
		Yes
C214		Please provide a brief description of the progress made in implementing Article 6 (Price and tax measures to reduce the demand for tobacco) in the past two years or since submission of your last report.
		Gradually increased tobacco taxes, which reached in 2022 level of 65 USD per 1000 cigarettes, with target to reach ~100 USD in 2025. In 2022 equalized taxes for all types of tobacco products and e-cigarettes, e-liquids
C215		Have you utilized the "Guidelines for implementation of Article 6 of the WHO FCTC" when developing or implementing policies in this area?
		Yes
C216		If you answered "Yes" to question C215 please provide details in the space below or refer to section H of the additional questionnaire available at this link. Response to this question or to the additional questionnaire is voluntary. https://extranet.who.int/dataformv3/862235?token={TOKEN}⟨=en
C217		If you have any other relevant information pertaining to but not covered in this section, please provide details in the space below.
C22		Protection from exposure to tobacco smoke Have you adopted and implemented, where appropriate, legislative, executive, administrative or other measures or have you implemented, where appropriate, programmes on any of the following:
C221		- banning, completely or partially, tobacco smoking in indoor workplaces, public transport, indoor public places and, as appropriate, other public places?
		Yes
1		What is the type/nature of the measure providing for the ban?
	1	national law
		Yes

	3	administrative and executive orders
		Yes
	4	voluntary agreements
	5	other measures (please specify in C223 below)
C223		Please provide a brief explanation of the type/nature and content of the measures providing for the ban.
C224		Do any of these measures provide for a mechanism/ infrastructure for enforcement?  Yes
C225		Please provide details of this system.
		According to the Law # 278, Agency for Public Health and General Inspectorate of Police are authorized to enforce the Law
1		Please specify the settings and extent/comprehensiveness of measures applied in indoor workplaces, public transport, indoor public places and, as appropriate, other public places. Indoor workplaces:
	1	government buildings
		Complete
	2	health-care facilities
		Complete
	3	educational facilities6
		Complete
	4	universities
		Complete
	5	private workplaces
		Complete
	6	other (please specify below)
C226aa		Please provide a brief explanation of any "other" policies in the space below
1		Please specify the settings and extent/comprehensiveness of measures applied in indoor workplaces, public transport, indoor public places and, as appropriate, other public places. Public transport:
	1	airplanes
		Complete
	2	trains
		Complete
	3	ferries

	4	ground public transport (buses, trolleybuses, trams)
		Complete
	5	private vehicles
		Complete
	6	other (please specify below)
		Partial
C226bb		Please provide a brief explanation of any "other" policies in the space below
1		Please specify the settings and extent/comprehensiveness of measures applied in indoor workplaces, public transport, indoor public places and, as appropriate, other public places. Indoor public places:
	1	cultural facilities
		Complete
	2	shopping malls
		Complete
	3	pubs and bars
		Complete
	4	nightclubs
		Complete
	5	restaurants
		Complete
	7	other (please specify below)
C226cc		Please provide a brief explanation of any "other" policies in the space below
C227		Please provide a brief summary of complete and partial measures, with specific details of the partial measures that have been implemented:
C227a		Banning tobacco smoking in indoor workplaces
		developed a Guide for managers with recommendation how to apply law provisions
C227b		Banning tobacco smoking in public transport
		Public transport companies and transport units are periodically verified by the police.
C227c		Banning tobacco smoking in indoor public places
		developed a Guide for managers of hospitality sector facilities with recommendation how to apply law provisions, also adopted a Instruction for Public health and Police officers how to enforce the Law
		Please provide a brief description of the progress made in implementing Article 8 (Protection from exposure to tobacco smoke) in the past two years or since submission of

C229	Have you utilized the "Guidelines for implementation of Article 8 of the WHO FCTC" when developing or implementing policies in this area?
	Yes
C2210	If you answered "Yes" to question C229 please provide details in the space below or refer to section B of the additional questionnaire available at this link. Response to this question or to the additional questionnaire is voluntary. https://extranet.who.int/dataformv3/862235?token={TOKEN}⟨=en
C2211	If you have any other relevant information pertaining to but not covered in this section, please provide details in the space below.
C23	Regulation of the contents of tobacco products Have you adopted and implemented, where appropriate, legislative, executive, administrative or other measures or have you implemented, where appropriate, programmes on any of the following:
C231	testing and measuring the contents of tobacco products? Yes
C232	testing and measuring the emissions of tobacco products?
	Yes
C233	regulating the contents of tobacco products?
	N/A
C234	regulating the emissions of tobacco products?
	Yes
C235	Please provide a brief description of the progress made in implementing Article 9 (Regulation of the contents of tobacco products) in the past two years or since submission of your last report.
C236	Have you utilized the "Guidelines for implementation of Articles 9 and 10 of the WHO FCTC" when developing or implementing policies in this area?
	Yes
C237	If you answered "Yes" to question C236 please provide details in the space below or refer to section C of the additional questionnaire available at this link. Response to this question or to the additional questionnaire is voluntary.  https://extranet.who.int/dataformv3/862235?token={TOKEN}⟨=en
C238	If you have any other relevant information pertaining to but not covered in this section, please provide details in the space below (e.g., whether your country 1) has incorporated product regulation in the national tobacco control legislation; 2) has access to either governmental or independent – not owned or controlled by the tobacco industry – laboratories for testing contents and/or emissions of tobacco products; 3) has regulated ingredients, such as flavours (e.g. menthol); 4) has regulated product characteristics, such as design features (e.g., cigarette ventilation); etc.).
C24	Regulation of tobacco product disclosures Have you adopted and implemented, where appropriate, legislative, executive, administrative or other measures or have you implemented, where appropriate, programmes on any of the following:
1	requiring manufacturers or importers of tobacco products to disclose to Government authorities information about the:

	1	contents of tobacco products?
		Yes
	2	emissions of tobacco products?
		Yes
1		requiring public disclosure of information about the:
	1	contents of tobacco products?
		Yes
	2	emissions of tobacco products?
		Yes
C243		Please provide a brief description of the progress made in implementing Article 10 (Regulation of tobacco product disclosures) in the past two years or since submission of your last report.
C244		Have you utilized the "Guidelines for implementation of Articles 9 and 10 of the WHO FCTC" when developing or implementing policies in this area?
		Yes
C245		If you answered "Yes" to question C244 please provide details in the space below or refer to section C of the additional questionnaire available at this link. Response to this question or to the additional questionnaire is voluntary. https://extranet.who.int/dataformv3/862235?token={TOKEN}⟨=en
C246		If you have any other relevant information pertaining to but not covered in this section, please provide details in the space below (e.g. whether your country has incorporated tobacco product disclosures in the national tobacco control legislation; has regulated the public disclosure of toxic constituents and emissions of tobacco products, aiming to raise public awareness and advance tobacco control policy; etc.).
C25		Packaging and labelling of tobacco products Have you adopted and implemented, where appropriate, legislative, executive, administrative or other measures or have you implemented, where appropriate, programmes on any of the following:
C251		requiring that packaging, individual cigarettes or other tobacco products do not carry advertising or promotion?
		Yes
C252		requiring that packaging and labelling do not promote a product by any means that are false, misleading, deceptive or likely to create an erroneous impression about its characteristics, health effects, hazards or emissions?
		Yes
C253		requiring that each unit packet and package of tobacco products and any outside packaging and labelling of such products carry health warnings describing the harmful effects of tobacco use?
		Yes
C254		ensuring that the health warnings are approved by the competent national authority?
		Yes

C255		ensuring that the health warnings are rotated?
		Yes
C256		ensuring that the health warnings are clear, visible and legible?
		Yes
C257		Does your law mandate, as a minimum, a style, size and colour of font to render the warning clear, visible and legible?
		Yes
C258		ensuring that the health warnings occupy no less than 30% of the principal display areas?
		No
C259		ensuring that the health warnings occupy 50% or more of the principal display areas?
		Yes
C2510		ensuring that health warnings are in the form of, or include, pictures or pictograms?
		Yes
C2511		Does the Government own the copyright to these pictures and pictograms?
		Yes
C2512		Would you grant a non-exclusive and royalty-free licence for the use of health warnings developed in your jurisdiction with other Parties?
		Yes
1		requiring that each unit packet and package of tobacco products and any outside packaging and labelling of such products contain information on relevant:
	1	constituents of tobacco products?
		Yes
	2	emissions of tobacco products?
		Yes
C2514		requiring that the warnings and other textual information appear on each unit packet and package and on any outside packaging and labelling in the principal language or languages of the country?
		Yes
C2515		Please provide a brief description of the progress made in implementing Article 11 (Packaging and labelling of tobacco products) in the past two years or since submission of your last report.
C2516		Have you utilized the "Guidelines for implementation of Article 11 of the WHO FCTC" when developing or implementing policies in this area?
		Yes
C2517		If you answered "Yes" to question C2516 please provide details in the space below or refer to section D of the additional questionnaire available at this link. Response to this question or to the additional questionnaire is voluntary. https://extranet.who.int/dataformv3/862235?token={TOKEN}⟨=en
C2518		If you have any other relevant information pertaining to or not covered in this section, please provide details in the space below.

C26		Education, communication, training and public awareness Have you adopted and implemented, where appropriate, legislative, executive, administrative or other measures or have you implemented, where appropriate, programmes on any of the following:
C261		educational and public awareness programmes? (Please refer to programmes implemented since submission of your two-year report.)
		Yes
1		To whom are these programmes targeted?
	1	adults or the general public
		Yes
	2	children and young people
		Yes
	3	men Yes
	4	women
	4	
	_	Yes
	5	pregnant women
		Yes
	6	ethnic groups
		No
	7	other
		No
C2621		Please specify
1		Do you reflect the following key differences among targeted population groups in educational and public awareness programmes?
	1	age
		Yes
	2	gender
		Yes
	3	educational background
		Yes
	4	cultural background
		Yes
	5	socioeconomic status
		No
	6	other
	-	No

C2631		Please specify
1		Do these educational and public awareness programmes cover:
	1	health risks of tobacco consumption?
		Yes
	2	health risks of exposure to tobacco smoke?
		Yes
	3	benefits of the cessation of tobacco use and tobacco-free lifestyles?  Yes
	4	adverse economic consequences of tobacco production?
		Yes
	5	adverse economic consequences of tobacco consumption?
		Yes
	6	adverse environmental consequences of tobacco production?
		No
	7	adverse environmental consequences of tobacco consumption?
		No
1		awareness and participation of the following agencies and organizations in development and implementation of intersectoral programmes and strategies for tobacco control:
	1	public agencies?
		Yes
	2	nongovernmental organizations not affiliated with the tobacco industry?
		Yes
	3	private organizations?
		No
	4	other
		No
C2651		Please specify
C266		Are the elaboration, management and implementation of communication, education, training and public awareness programmes guided by research and do they undergo pre-testing, monitoring and evaluation?
		Yes
1		Are appropriate and special training or sensitization and awareness programmes on tobacco control addressed to:
	1	health workers?
		Yes
	1	

1	2	community workers?
		Yes
	3	social workers?
		Yes
	4	media professionals?
		Yes
	5	educators?
		Yes
	6	decision-makers?
		No
	7	administrators?
		No
	8	other
		No
C2671		Please specify
C268		Please provide a brief description of the progress made in implementing Article 12 (Education, communication, training and public awareness) in the past two years or since submission of your last report.
		During 2021-2022 trained more than 200 health and social workers on sensitization and awareness programmes on tobacco control
C269		Have you utilized the "Guidelines for implementation of Article 12 of the WHO FCTC" when developing and implementing policies in this area?
		Yes
C2610		If you answered "Yes" to question C269 please provide details in the space below or refer to section E of the additional questionnaire available at this link. Response to this question or to the additional questionnaire is voluntary. https://extranet.who.int/dataformv3/862235?token={TOKEN}⟨=en
C2611		If you have any other relevant information pertaining to but not covered in this section, please provide details in the space below.
C27		Tobacco advertising, promotion and sponsorship Have you adopted and implemented, where appropriate, any legislative, executive, administrative or other measures or have you implemented, where appropriate, programmes:
C271		instituting a comprehensive ban on all tobacco advertising, promotion and sponsorship?
		Yes
1		Does your ban cover:
	1	display and visibility of tobacco products at points of sales?
		Yes
1		

		Yes
	3	the global Internet?
		No
	4	brand stretching and/or brand sharing?
	·	No
	5	product placement as a means of advertising or promotion?
	6	Yes the depiction of takens at takens use in autortainment madic products?
	6	the depiction of tobacco or tobacco use in entertainment media products?
	_	Yes
	7	tobacco sponsorship of international events or activities and/or participants therein?
		Yes
	8	contributions from tobacco companies to any other entity for "socially responsible causes" and/or any other activities implemented under the umbrella of "corporate social responsibility" by the tobacco industry?
		Yes
	9	cross-border advertising, promotion and sponsorship originating from your territory?
		Yes
	10	the same forms of cross-border advertising, promotion and sponsorship entering your territory for which domestic regulation apply?
		Yes
C273		are you precluded by your constitution or constitutional principles from undertaking a comprehensive ban on tobacco advertising, promotion and sponsorship?
		N/A
C274		applying restrictions on all tobacco advertising, promotion and sponsorship?
		N/A
C275		applying restrictions on cross-border advertising, promotion and sponsorship originating from your territory with cross-border effects?
		N/A
C276		prohibiting those forms of tobacco advertising, promotion and sponsorship that promote a tobacco product by any means that are false, misleading, deceptive or likely to create an erroneous impression about its characteristics, health effects, hazards or emissions?
		N/A
C277		requiring that health or other appropriate warnings or messages accompany all tobacco advertising, promotion and sponsorship?
		N/A
C278		restricting the use of direct or indirect incentives that encourage the purchase of tobacco products by the public?
		N/A
C279		requiring the disclosure to relevant Government authorities of expenditures by the tobacco industry on advertising, promotion and sponsorship not yet prohibited?
		N/A
1		restricting tobacco advertising, promotion and sponsorship on:
	1	1

	1	radio?
		N/A
	2	television?
		N/A
	3	print media?
		N/A
	4	the domestic Internet?
		N/A
	5	the global Internet?
		N/A
	6	other media?
		N/A
C27101		Please specify
1		restricting tobacco sponsorship of:
	1	international events and activities?
		N/A
	2	participants therein?
		N/A
C2712		cooperating with other Parties in the development of technologies and other means necessary to facilitate the elimination of cross-border advertising?
		No
C2713		imposing penalties for cross-border advertising equal to those applicable to domestic advertising, promotion and sponsorship originating from your territory in accordance with national law?
		Yes
C2714		Please provide a brief description of the progress made in implementing Article 13 (Tobacco advertising, promotion and sponsorship) in the past two years or since submission of your last report.
C2715		Have you utilized the "Guidelines for implementation of Article 13 of the WHO FCTC" when developing and implementing policies in this area?  Yes
C2716		If you answered "Yes" to question C2715 please provide details in the space below or refer to section F of the additional questionnaire available at this link. Response to this question or to the additional questionnaire is voluntary.  https://extranet.who.int/dataformv3/862235?token={TOKEN}⟨=en
C2717		If you have any other relevant information pertaining to but not covered in this section, please provide details in the space below.
		In August 2020 introduced display ban for all types of tobacco products, e-cigarettes and devices for HTP and e-cigarettes at points of sales?

C28		Demand reduction measures concerning tobacco dependence and cessation Have you adopted and implemented, where appropriate, legislative, executive, administrative or other measures or have you implemented, where appropriate, programmes on any of the following:
C281		developing and disseminating appropriate, comprehensive and integrated guidelines based on scientific evidence and best practices?
		Yes
1		programmes to promote cessation of tobacco use, including:
	1	media campaigns emphasizing the importance of quitting?  Yes
	2	programmes specially designed for underage girls and young women?
		No
	3	programmes specially designed for women?
		No
	4	programmes specially designed for pregnant women?
	1	
	5	No
		telephone quitlines?
	0	Yes
	6	local events, such as activities related to World No Tobacco Day or National No Smoking Day, if appropriate?
		Yes
	7	other?
		No
C2821		Please specify
1		design and implementation of programmes aimed at promoting the cessation of tobacco use, in such locations as:
	1	educational institutions?
		No
	2	health-care facilities?
		Yes
	3	workplaces?
		Yes
	4	sporting environments?
		No
	5	other?
		No
C2831		Please specify

1		inclusion of diagnosis and treatment of tobacco dependence and counselling services for cessation of tobacco use in national programmes, plans and strategies for:
	1	tobacco control?
		Yes
	2	health?
		Yes
	3	education?
		No
C285		inclusion of programmes on the diagnosis and treatment of tobacco dependence in your health-care system?
		Yes
1		Which structures in your health-care system provide programmes for the diagnosis and treatment of tobacco dependence?
	1	primary health care
		Yes
	2	secondary and tertiary health care
		No
	3	specialist health-care systems (please specify below)
		No
	4	specialized centres for cessation counselling and treatment of tobacco dependence
		Yes
	5	rehabilitation centres
		No
1		Are the services provided in these settings covered by public funding or reimbursement schemes?
	1	primary health care
		Fully
	2	secondary and tertiary health care
	3	specialist health-care systems (please specify below)
	4	specialized centres for cessation counselling and treatment of tobacco dependence
		Partially
	5	rehabilitation centres
	6	other (please specify below)

C287b		Please provide other details in the space below.
1		Which health and other professionals are involved in programmes offering treatment for tobacco dependence and counselling services? Health professionals including:
	1	physicians
		Yes
	2	dentists
		No
	3	family doctors
		Yes
	4	practitioners of traditional medicine
		No
	5	other medical professionals (please specify below)
		Yes
	6	nurses
		No
	7	midwives
		No
	8	pharmacists
		No
	9	Community workers
		No
	10	Social workers
		No
	11	other (please specify)
		No
1		training on tobacco dependence treatment incorporated into the curricula of health professional training at pre- and post-qualification levels at the following schools:
	1	medical?
		Yes
	2	dental?
		No
	3	nursing?
		No
	4	pharmacy?
	•	No No
C2810		facilitating accessibility and/or affordability of pharmaceutical products for the treatment

		tobacco dependence?
		No
C2811		Where and how can these products be legally purchased in your country?
1		Which pharmaceutical products are legally available for the treatment of tobacco dependence in your jurisdiction?
	1	nicotine replacement therapy
		N/A
	2	bupropion
		N/A
	3	varenicline
		N/A
	4	other (please specify)
		N/A
1		Are the costs of these products covered by public funding or reimbursement?
	1	nicotine replacement therapy
	2	bupropion
	3	varenicline
	4	other (please specify below)
C2813b		Please provide other details in the space below.
C2814		Please provide a brief description of the progress made in implementing Article 14 (Demand reduction measures concerning tobacco dependence and cessation) in the past two years or since submission of your last report.
C2815		Have you utilized the "Guidelines for implementation of Article 14 of the WHO FCTC" when developing and implementing policies in this area?
		Yes
C2816		Please provide details in the space below or refer to section G of the additional questionnaire. Response to this question or to the additional questionnaire is voluntary. https://extranet.who.int/dataformv3/862235?token={TOKEN}⟨=en
C2817		If you have any other relevant information pertaining to but not covered in this section, please provide details in the space below.

# C3. MEASURES RELATING TO THE REDUCTION OF THE SUPPLY OF TOBACCO

C3	With reference to Articles 15–17
C31	Illicit trade in tobacco products Have you adopted and implemented, where appropriate, legislative, executive, administrative or other measures or have you implemented, where appropriate, programmes on any of the following:
C311	requiring marking of all unit packets and packages of tobacco products and any outside packaging of such products to assist in determining the origin of the product?
	Yes
C312	requiring marking of all unit packets and packages of tobacco products and any outside packaging of such products to assist in determining whether the product is legally sold on the domestic market?
	Yes
C313	requiring that unit packets and packages of tobacco products for retail and wholesale use that are sold on the domestic market carry the statement: "Sales only allowed in" or carry any other effective marking indicating the final destination of the product?
	No
C314	developing a practical tracking and tracing regime that would further secure the distribution system and assist in the investigation of illicit trade?
	No
C315	requiring that marking is presented in legible form and/or appears in the principal language or languages of the country?
	Yes
C316	requiring the monitoring and collection of data on cross-border trade in tobacco products, including illicit trade?
	Yes
C317	facilitating the exchange of this information among customs, tax and other authorities, as appropriate, and in accordance with national law and applicable bilateral and multilateral agreements?
	Yes
C318	enacting or strengthening legislation, with appropriate penalties and remedies, against illicit trade in tobacco products, including counterfeit and contraband cigarettes?
	Yes
C319	requiring that confiscated manufacturing equipment, counterfeit and contraband cigarettes and other tobacco products derived from illicit trade are destroyed, using environment-friendly methods where possible, or disposed of in accordance with national law?
	Yes
C3110	adopting and implementing measures to monitor, document and control the storage and distribution of tobacco products held or moving under suspension of taxes or duties?
	Yes
C3111	enabling the confiscation of proceeds derived from illicit trade in tobacco products?
	Yes
C3112	promoting cooperation between national agencies and relevant regional and international intergovernmental organizations in investigations, prosecutions and proceedings, with a view to eliminating illicit trade in tobacco products, with special emphasis on cooperation at regional and subregional levels?

		Yes
C3113		licensing or other actions to control or regulate production and distribution in order to prevent illicit trade?
		Yes
C3114		Please provide a brief description of the progress made in implementing Article 15 (Illicit trade in tobacco products) in the past two years or since submission of your last report.
		By the Law 61/2022 of 17 March 2022 was approved Accession of the Republic of Moldova to FCTC Protocol on eliminating illicit trade in tobacco products. On 10 May 2022 Republic of Moldova became a Party to the Protocol. Protocol provisions transposed into national legislation by the Law 25/2023.
C3115		If you have any other relevant information pertaining to but not covered in this section, please provide details in the space below.
C32		Sales to and by minors Have you adopted and implemented, where appropriate, legislative, executive, administrative or other measures or have you implemented, where appropriate, programmes on any of the following:
C321		prohibiting the sales of tobacco products to minors?
		Yes
C321a		Please specify the legal age:
		18
C322		requiring that all sellers of tobacco products place a clear and prominent indicator inside their point of sale about the prohibition of tobacco sales to minors?
		Yes
C323		requiring that, in case of doubt, each seller of tobacco products requests that the purchaser provides appropriate evidence of having reached full legal age?
		Yes
C324		banning the sale of tobacco products in any manner by which they are directly accessible, such as open store shelves?
		Yes
C325		prohibiting the manufacture and sale of sweets, snacks, toys or any other objects in the form of tobacco products which appeal to minors?
		Yes
C326		prohibiting the sale of tobacco products from vending machines?
		Yes
C327		Do you ensure that tobacco vending machines are not accessible to minors and/or do not promote the sale of tobacco products to minors?
		N/A
1		prohibiting and/or promoting the prohibition of the distribution of free tobacco products:
	1	to the public?
		Yes
	2	to minors?
		Yes

C329		prohibiting the sale of cigarettes individually or in small packets?
		Yes
C3210		providing for penalties against sellers and distributors in order to ensure compliance?
		Yes
C3211		prohibiting the sales of tobacco products by minors?
		Yes
C3212		Please provide a brief description of the progress made in implementing Article 16 (Sales to and by minors) in the past two years or since submission of your last report.
C3213		If you have any other relevant information pertaining to but not covered in this section, please provide details in the space below.
C33		Provision of support for economically viable alternative activities Have you adopted and implemented, where appropriate, measures or programmes on any of the following:
1		promoting economically viable and sustainable alternatives for:
	1	tobacco growers?
		Yes
	2	tobacco workers?
		Not applicable
	3	tobacco individual sellers?
		Not applicable
C332		Please provide a brief description of the progress made in implementing Article 17 (Provision of support for economically viable alternative activities) in the past two years or since submission of your last report.
		Agricultural field with tobacco crops were reduced constantly, including by 20% in last 2 years
C333		Have you utilized the "Policy options and recommendations on economically sustainable alternatives to tobacco growing (in relation to Articles 17 and 18 of the WHO FCTC)" when developing and implementing policies in this area?
		Yes
C334		Please provide details in the space below or refer to section I of the additional questionnaire. Response to this question or to the additional questionnaire is voluntary. https://extranet.who.int/dataformv3/862235?token={TOKEN}⟨=en
C335		If you have any other relevant information pertaining to but not covered in this section, please provide details in the space below.
1		

# **C4. OTHER MEASURES AND POLICIES**

C4		With reference to Articles 18–21
C41		Protection of the environment and the health of persons Have you adopted and implemented, where appropriate, legislative, executive, administrative or other measures or have you implemented, where appropriate, programmes on any of the following:
1		implementing measures in respect of tobacco cultivation within your territory, which take into consideration:
	1	the protection of the environment? Yes
	2	the health of persons in relation to the environment?  Yes
1		implementing measures in respect of tobacco manufacturing within your territory, which take into consideration:
	1	the protection of the environment?  Yes
	2	the health of persons in relation to the environment?  Yes
C413		Please provide a brief description of the progress made in implementing Article 18 (Protection of the environment and the health of persons) in the past two years or since submission of your last report.
C414		Have you utilized the "Policy options and recommendations on economically sustainable alternatives to tobacco growing (in relation to Articles 17 and 18 of the WHO FCTC)" when developing and implementing policies in this area?  No
C415		If you answered "Yes" to question C414 please provide details in the space below or refer to section I of the additional questionnaire available at this link. Response to this question or to the additional questionnaire is voluntary.  https://extranet.who.int/dataformv3/862235?token={TOKEN}⟨=en
C416		If you have any other relevant information pertaining to but not covered in this section, please provide details in the space below.
C42		Liability Have you adopted and implemented, where appropriate, legislative, executive, administrative or other measures or have you implemented, where appropriate, programme on any of the following:
SQ001		Does your tobacco control legislation contain measures regarding criminal liability for any violations of that tobacco control legislation?

		Yes
SQ001		Do you have separate criminal liability provisions in relation to tobacco control (outside of the tobacco control legislation)?
	SQ001	
		Not applicable
SQ001		Do you have any civil liability measures that are specific to tobacco control?
	SQ001	
		Yes
SQ001		Do you have any general civil liability provisions that could apply to tobacco control?
	SQ001	
		Yes
SQ001		Do you have civil or criminal liability provisions that provide for compensation for adverse health effects and/or for reimbursement of medical, social or other relevant costs?
	SQ001	
		Yes
SQ001		?Has any person in your jurisdiction launched any criminal and/or civil liability action, including compensation where appropriate, against any tobacco company in relation to any adverse health effect caused by tobacco use?
	SQ001	
		No
SQ001		Have you taken, as appropriate, any legislative, executive, administrative and/or other actio against the tobacco industry for full or partial reimbursement of medical, social and other relevant costs related to tobacco use in your jurisdiction?
	SQ001	
		Yes
C428		Please provide a brief description of any progress made, as appropriate, in implementing Article 19 (Liability) in the past two years or since submission of your last report.
		Amended Penalty and Fine Codes
C429		If you have any other relevant information pertaining to but not covered in this section, please provide details in the space below.
C43		Research, surveillance and exchange of information Have you adopted and implemented, where appropriate, legislative, executive, administrative or other measures or have you implemented, where appropriate, programmes on any of the following:

	1	determinants of tobacco consumption?
		Yes
	2	consequences of tobacco consumption?
		Yes
	3	social and economic indicators related to tobacco consumption?
		Yes
	4	tobacco use among women, with special regard to pregnant women?
		Yes
	5	the determinants and consequences of exposure to tobacco smoke?
		Yes
	6	identification of effective programmes for the treatment of tobacco dependence?
		No .
	7	identification of alternative livelihoods?
		No
C4311		Please specify
04311		Trease specify
C422		training and compart for all passage appared in tabases control activities including
C432		training and support for all persons engaged in tobacco control activities, including research, implementation and evaluation?
		Yes
1		a national system for epidemiological surveillance of:
	1	patterns of tobacco consumption?
		Yes
	2	determinants of tobacco consumption?
		Yes
	3	consequences of tobacco consumption?
		Yes
	4	social, economic and health indicators related to tobacco consumption?
	7	Yes
	5	
	3	exposure to tobacco smoke?
0.400.4		Yes
C4331		Please specify
C434		Please list all surveys, including the year of the survey, that you have undertaken in the past.
		GYTS, 2003, Republic of Moldova Demographic and health Survey, Republic of Moldova, 2005 GYTS, 2008, Republic of Moldova MICS Survey in Republic of Moldova, 2012, STEPS Survey, 2013 GYTS, 2013, Republic of Moldova, KAP Survey 2017 GYTS, 2019, Republic of Moldova STEPS Survey, 2021
C435		Does your country have any plans to repeat any of the above or to undertake a new tobacco survey within three to five years of your last survey? Please provide details in the space below.

		To repeat MICS Survey in 2024
1		regional and global exchange of publicly available national:
	1	scientific, technical, socioeconomic, commercial and legal information?  Yes
	2	information on the practices of the tobacco industry?  No
	3	information on the cultivation of tobacco?  No
1		an updated database of:
	1	laws and regulations on tobacco control?  Yes
	2	information about the enforcement of laws on tobacco control?  Yes
	3	pertinent jurisprudence? No
C438		Please provide a brief description of the progress made in implementing Article 20 (Research, surveillance and exchange of information) in the past two years or since submission of your last report.
C439		If you have any other relevant information pertaining to but not covered in this section, please provide details in the space below (e.g. whether you included information on WHO FCTC implementation in your Voluntary National Review (VNR) on the Sustainable Development Goals (SDGs), related to target 3.a).

# D. INTERNATIONAL COOPERATION AND ASSISTANCE

D0		Pursuant to Article 21.1(c) and in accordance with Article 26, have you either provided or received financial or technical assistance (be it through unilateral, bilateral, regional, subregional or other multilateral channels, including relevant regional and international intergovernmental or nongovernmental organizations and financial and development institutions) for the development and strengthening of multisectoral, comprehensive tobacco control programmes of developing country Parties and Parties with economies in transition in any of the following areas:
1		development, transfer and acquisition of technology, knowledge, skills, capacity and expertise related to tobacco control?
	1	Assistance provided
		Yes
	2	Assistance received
		Yes
1		provision of technical, scientific, legal and other expertise to establish and strengthen national tobacco control strategies, plans and programmes?
	1	Assistance provided
		Yes
	2	Assistance received
		Yes
1		appropriate training or sensitization programmes for appropriate personnel in accordance with Article 12?
	1	Assistance provided
		Yes
	2	Assistance received
		Yes
1		provision of the necessary material, equipment and supplies, as well as logistic support, for tobacco control strategies, plans and programmes?
	1	Assistance provided
		Yes
	2	Assistance received
		Yes
1		identification of methods for tobacco control, including comprehensive treatment of nicotine addiction?
	1	Assistance provided
		No
	2	Assistance received

		No
1		promotion of research to increase the affordability of comprehensive treatment of nicotine addiction?
	1	Assistance provided
		No
	2	Assistance received
		No
D7		Please identify the Party or Parties from which assistance was received or to which assistance was provided.
		WHO/Europe, European Union, FCTC Secretariat,
D8		Please provide information about any assistance provided or received in the space below, including any support received from nongovernmental organizations (please, specify).
		Support in transfer and acquisition of knowledge, skills, capacity and expertise related to tobacco control for development of national Tobacco control strategies - after Needs Assessment report in 2010 was set an action plan to develop comprehensive Tobacco control policies. Moldova received technical assistance from WHO, WHO experts for development of the first National Tobacco Control Programme for the years 2012-2016, 3 National Policy Dialogues on Tobacco Control in 2014, 2015 and 2016, new Tobacco Control Law adopted on 29.05.2015 which entered into force on 17.09.2015, implementation in 2018 a national communication campaign. focused on current and potential users of tobacco. In 2017 Republic of Moldova become a part of the JATC (Joint Action Tobacco Control Program for implementation of the EU Directive 40 on Tobacco Products), process started in December 2017, and National Agency for Public Health become a collaborating partner for JATC.
D9		If you have not received or provided assistance in any of the aforementioned areas, please identify any financial or technical assistance that may be under consideration, if appropriate.
D10		Have you encouraged relevant regional and international intergovernmental organizations and financial and development institutions in which you are represented to provide financial assistance for developing country Parties and for Parties with economies in transition to assist them in meeting their obligations under the Convention?  No
D11		Please provide details in the space below.

# **E. PRIORITIES AND COMMENTS**

E1		What are the priorities for implementation of the WHO Framework Convention on Tobacco Control in your jurisdiction?
		1. To adopt national Regulation and create mechanism for implementation of tracking and tracing system for tobacco products to eliminate illicit trade, according to obligations as a Party to Protocol, 2. To assure harmonization with EU Legislation of Tobacco Control Law and implement its new provisions, especially what is related to novel tobacco products. 3. To continue to increase tobacco taxes. 4. To prevent and counteract tobacco industry interference, 5. To stop increasing and reduce smoking prevalence, focusing a special attention to novel tobacco products 6.To maintain active Coordination Council on Tobacco Control, 7.To carry a new communication campaign in 2023, 8. To strengthen capacities of Cessation Service, 9. To strengthen capacities of Public Health Inspectorate
E2		Have you identified any specific gaps between the resources available and the needs assessed for implementing the WHO Framework Convention on Tobacco Control?
		Yes
E3		Please provide details in the space below.
		<ul> <li>Not enough funds for tobacco control measures, for communication campaigns, also insufficient involvement of public authorities, - More knowledge and regulations are necessary to counteract increasing use of novel tobacco products, - More support needed for optimization of Cessation Service, - Significant resources are required for implementation of tracking and tracing system for tobacco products to eliminate illicit trade</li> </ul>
E4		What, if any, are the constraints or barriers, other than lack of resources, you have encountered in implementing the Convention?
		- Insufficient involvement in tobacco control measures of some relevant ministries as of Economy and of Finance, - Insufficient trained staff in National Agency for Public Health for Law on Tobacco Control fully enforcement
1		Do you have any of the following products available on your national tobacco market?
	1	smokeless tobacco products
		Yes
	2	water pipe tobacco
		Yes
	3	Electronic Nicotine Delivery Systems (ENDS)
		Yes
	4	Electronic Non-Nicotine Delivery Systems (ENNDS)
		Yes
	5	heated tobacco products (HTPs)
		Yes
1		Have you adopted and implemented any policy or regulation that is specific to the following tobacco products?
	4	amelialasa tahansa mudusta
	1	smokeless tobacco products
	2	Yes water pine takens
	2	water pipe tobacco
	I	Yes
	3	Electronic Nicotine Delivery Systems (ENDS)

5	Electronic Non-Nicotine Delivery Systems (ENNDS) Yes
5	Yes
5	
	heated tobacco products (HTPs)
	Yes
	If you have any relevant information related to questions E5 and E6, please provide details in the space below.
	Do you have a costed national tobacco control plan or strategy?
	N/A
	If you answered "Yes" to question E8, is this costed national tobacco control plan or strategy fully funded?
	N/A
	Please attach the costed plan or strategy here.
	Please provide the government's expenditure on tobacco control, for the latest year available, in your country's currency.
	none
	Have you adopted and implemented any national legislative, executive, administrative and/or other measures that go beyond the requirements of the Convention in line with Article 2.1 (e.g, endgame strategies, smoke-free generations, tobacco free villages or cities)?
	N/A
	If you answered "Yes" to question E10, please provide details.
	Please attach any documentation relevant to any sections of the reporting instrument.
	Please provide any other relevant information not covered elsewhere that you consider important.
	Your suggestions for further development and revision of the reporting instrument: